

# CURRICULUM VITAE

---

**Kevin John Black, M.D.**

February 9, 2021

## CITIZENSHIP

USA

## ADDRESS AND PHONE

Office: 314-362-5041

Department of Psychiatry  
Campus Box 8134  
Washington University School of Medicine  
660 S. Euclid Ave.  
St. Louis, MO 63110-1093

E-mail: [kevin@WUSTL.edu](mailto:kevin@WUSTL.edu)

## PRESENT POSITION

7/2010 – present      Professor of Psychiatry, of Neurology, of Radiology and of Neuroscience  
Washington University School of Medicine

## EDUCATION / TRAINING

8/15/1986              B.S., Mathematics, Brigham Young University, Provo, Utah  
5/13/1990              M.D., Duke University School of Medicine, Durham, North Carolina  
7/1990 – 6/1994      Residency in Psychiatry, Barnes Hospital / Washington University School of  
Medicine (PGY-1 to PGY-4), St. Louis, Missouri  
7/1994 – 6/1996      Movement Disorders and Neuroimaging Fellowship (Joel S. Perlmutter, M.D.,  
mentor), Department of Neurology, Washington University School of  
Medicine, St. Louis, Missouri

## ACADEMIC POSITIONS / EMPLOYMENT

### At Washington University School of Medicine:

7/1990 - 6/1994      Associate in Psychiatry (House Staff)  
7/1994 - 9/1996      Instructor in Psychiatry  
7/1994 - 12/1998     Instructor in Neurology  
7/1996 - 9/1996      Instructor in Radiology  
10/1996 - 6/2004     Assistant Professor of Psychiatry and Radiology  
1/1999 - 6/2004      Assistant Professor of Neurology  
7/2004 - 6/2010      Associate Professor of Psychiatry, Neurology, and Radiology (with tenure)  
6/2005 - 6/2010      Associate Professor of Neurobiology  
7/2010 - present      Professor of Psychiatry, of Neurology, of Radiology, and of Neuroscience

## CLINICAL TITLE AND RESPONSIBILITIES

1996-present Attending Psychiatrist, Barnes-Jewish Hospital  
 1996-present Neuropsychiatrist, Washington University Movement Disorders Center

## TEACHING TITLE AND RESPONSIBILITIES

1994-present Attending physician supervising residents (clinical work and psychotherapy supervision)  
 1996-present Course director, neuroimaging for residents  
 7/1996-11/2009:  
     Coursemaster, third year medical student psychiatry clerkship  
 1997-2007 Co-director of medical student education in psychiatry (position discontinued)  
 1998-present Director, neuropsychiatry elective for psychiatry residents  
 8/2007 Expert content reviewer for NBME Psychiatry boards examination  
 8/2007 Appointment to Division of Biology and Biomedical Science (*i.e.* eligible to mentor Ph.D. students at the medical campus). Renewed 6/2013 for 5 years.

## UNIVERSITY COMMITTEES

1990-1993, 1996-2009 Member, Psychiatry Department Educational Policy Committee  
 1997 Member, Washington University School of Medicine LCME Institutional Self-Study Task Force (Subcommittee on GME, clinical teaching facilities, and clinical departments)  
 1997 - 2009 Alternate, Washington University School of Medicine Human Studies Committee (IRB)  
 7/2019 *ad hoc* member, WUSM Human Research Protection Office (IRB)

## HOSPITAL APPOINTMENTS

1992 - 1994 Medical Staff, Malcolm Bliss Mental Health Center  
 1994 - 1996 Assistant Attending Psychiatrist, Barnes Hospital  
 1994 - 1996 Consulting Psychiatrist, Jewish Hospital  
 1996 - present Attending Psychiatrist, Barnes-Jewish Hospital

## MEDICAL LICENSURE AND CERTIFICATION

### Medical licensure

8/8/1991 - Missouri permanent license (#37001)

### Board Certification

10/14/1995 - 12/31/2005 [American Board of Psychiatry and Neurology \(ABPN\)](#), Psychiatry (certificate #41643)  
 7/25/2005 - 12/31/2015 ABPN, Psychiatry – 10-year recertification (certificate #41643)  
 11/06/1996 - 12/31/2006 ABPN, Added Qualifications in Geriatric Psychiatry (certificate #1709)  
 9/30/2006 - 12/31/2016 [United Council for Neurologic Subspecialties \(UCNS\)](#) certification in Behavioral Neurology & Neuropsychiatry (certificate #BNNP00211-06)  
 4/25/2016 ABPN, Psychiatry recertification (certificate #41643)  
 4/25/2016 ABPN, Geriatric Psychiatry recertification (certificate #1709)

11/30/2016 - 12/31/2026 UCNS, Behavioral Neurology & Neuropsychiatry recertification  
(certificate #BNNP00562-16)  
2019- UCNS, continuous certification (certificate # BNNP440)

**Other Certifications**

2000-2021 Radioactive materials authorization #0762 (nonhuman research use)  
9/2008-present Authorized User of PET radiopharmaceuticals for human use

**HONORS AND AWARDS**

1980 Eagle Scout  
1986 University Honors graduate, Brigham Young University  
1988 - 1989 Howard Hughes Medical Institute—NIH Research Scholarship  
1990 1st prize, Duke University—John A. Hartford Foundation Program for Geriatrics Student Scholars  
1990-91 and 1991-92 Voted Outstanding Teaching Resident for psychiatry by Washington University medical students  
1993 National Library of Medicine Fellowship to attend NIH/MBL Medical Informatics course  
1993 Mead Johnson Fellow in Academic Psychiatry, Association for Academic Psychiatry  
1993 Southern Psychiatric Association Annual Award for Psychiatrists in Training  
1994 Upjohn Resident Research Award, Washington University Department of Psychiatry  
7/1996 - 6/1998 NARSAD Young Investigator Award  
7/1999 - 6/2001 NARSAD Young Investigator Award (2<sup>nd</sup> award)  
12/2001 American College of Neuropsychopharmacology (ACNP) / Bristol-Myers Squibb Travel Award  
5/2003 Washington University Center for Aging Pilot Research Award  
2005-2019 Elected by his peers for inclusion in **Best Doctors in America®**  
1/2006 Named a Fellow of the American Neuropsychiatric Association  
9/2006 Hope Award from the St. Louis chapter of the HDSA (Huntington Disease Society of America)  
2009-2019 Listed in Castle Connolly's **America's Top Doctors®**  
2015 Named a Fellow of CINP, the International College of Neuropsychopharmacology  
7/2016 Invited participant, 2016 Sci Foo camp

## EDITORIAL RESPONSIBILITIES

### Editorial board

- 2013-present Editorial Board, **PeerJ** (<https://PeerJ.com/KJB>)
- 2014 Co-editor for [special issue on Tourette syndrome research](#), **Journal of Obsessive-Compulsive and Related Disorders**
- 2014-present [Associate Editor](#), Brain Imaging Methods section of **Frontiers in Neuroscience**
- 2014-present Advisor to **Tics** channel, **F1000Research** (<http://f1000research.com/channels/tics>)
- 2015-present [Associate Editor](#), **Journal of Neuropsychiatry and Clinical Neurosciences**  
(official journal of the American Neuropsychiatric Association)
- 2015-present [Associate Editor](#), Neuropharmacology section of **Frontiers in Pharmacology**
- 2021 Guest editor (with Deanna Greene) for special issue, Clinical and Pathophysiological Studies of Tourette Syndrome, **Journal of Clinical Medicine**

### Ad hoc reviewer (see also <https://publons.com/a/13101>)

- 1994- Southern Medical Journal
- 1996- Neurology
- 1997- Neuroscience
- 1997- Journal of Neurology, Neurosurgery, and Psychiatry
- 1997- American Journal on Mental Retardation [now American Journal on Intellectual and Developmental Disabilities]
- 1997- Journal of Computer Assisted Tomography
- 1998- Journal of Neuroscience
- 1999- Psychiatry Research – Neuroimaging
- 2001- Cerebral Cortex
- 2003- Journal of Neuropsychiatry and Clinical Neurosciences
- 2004- Biological Psychiatry
- 2005- Human Brain Mapping
- 2007- American Journal of Psychiatry
- 2008- Neuropediatrics
- 2008- Molecular Psychiatry
- 2008- Drug and Alcohol Dependence
- 2009- Archives of General Psychiatry [now JAMA Psychiatry]
- 2010- NeuroImage
- 2012- Journal of Psychiatric Practice
- 2013- PeerJ
- 2013- Brain
- 2013- Psychiatry Journal
- 2013- F1000Research
- 2014- PLOS ONE
- 2014- Developmental Cognitive Neuroscience
- 2015- Psychopharmacology
- 2016- Brain Sciences
- 2018- IEEE Journal of Biomedical and Health Informatics
- 2018- Movement Disorders
- 2018- Medicina Internacia Revuo
- 2018- Cortex

2020- American Journal of Geriatric Psychiatry  
2020- Neurotherapeutics  
2020- Science Translational Medicine

## **NATIONAL PANELS, COMMITTEES, BOARDS**

### **NIH study section member**

10/2007-6/2011 NIH Clinical Neuroscience and Neurodegeneration Study Section (CNN);  
formerly Clinical Neuroscience and Disease (CND-E90s)

### **NIH advisory committees**

12/2003 NINDS/NIMH Work Group on Depression and Parkinson's Disease  
11/3-4/2016 NIMH Motor Systems Domain RDoC workshop

### **FDA advisory committee**

10/17/2011 FDA Peripheral and Central Nervous System Drugs Advisory Committee

### **DSM-5-TR**

2019 Contributor, chapter on "Medication-Induced Movement Disorders and Other  
Adverse Effects of Medication"

### **Ad hoc reviewer**

1996 Alzheimer's Disease and Related Disorders Research Program  
3/2003 NIMH Conte Centers Special Emphasis Panel  
1/2004, 2/2005 NIH review panel for NTRC (formerly MDCN-4), Human Brain Project  
9/2005 *ad hoc* review panel for United States Army Medical Research and Materiel Command  
(USAMRMC)  
10/2005, 3/2006, 10/2006, 3/2007 (CNN); 6/2007 (CND-E90s); 2007-2011 NIH Clinical  
Neuroscience and Disease (CND) Study Section  
1/2006 *ad hoc* reviewer for TSA Scientific Advisory Board  
7/2007 NIMH Conflict of Interest Special Emphasis Panel  
7/2009 NIH ARRA review committee ZMH1-ERB-E-(07)  
3/2010 AAAS Research Competitiveness Program  
7/2013 NIH Special Emphasis Panel ZRG1 BDCN-C (02) S  
10/2013 *ad hoc* reviewer for WUSTL Hope Center  
2/2017 *ad hoc* reviewer for NIH Clinical Neuroscience and Neurodegeneration (CNN) Study  
Section  
10/2018 *ad hoc* reviewer for Parkinson Study Group  
2/2019 *ad hoc* reviewer for Tourettes Action (UK charity)

## **PROFESSIONAL SOCIETIES AND ORGANIZATIONS**

1993- American Neuropsychiatric Association  
Committee on Research, 2000-2015  
Fellow, 2006  
One of 6 elected Advisory Council members, 2011-2014  
Program Committee, 2014-  
1994- The Movement Disorder Society (now International Parkinson and Movement  
Disorder Society)

- 1994- Society for Neuroscience  
1995- Tourette Association of America (formerly Tourette Syndrome Association)  
Professional membership and physician referral list;  
Medical advisor, Greater Missouri chapter, 1996-present;  
(First) TSA Neuroimaging Consortium, 2002-2004;  
TSA Clinical Trials Consortium, 2006;  
Co-director, (new) TSA Neuroimaging Consortium, 2010-  
1996- American Parkinson Disease Association  
Medical advisor, St. Louis chapter  
2015- The International College of Neuropsychopharmacology (CINP)  
Fellow, 2015

### **MAJOR INVITED PROFESSORSHIPS AND LECTURESHIPS**

1. Diagnosing depression after stroke. Resident research award lecture, Southern Psychiatric Association annual meeting. Tucker's Town, Bermuda, 1 October 1993.
2. Treatment of Tourette syndrome. Invited lecture, Tourette Syndrome Association of Georgia and South Carolina, Atlanta, Georgia, 27 September 2000.
3. Risks of developing additional criteria for depression in Parkinson disease. Invited lecture at NINDS Consensus Conference on Diagnosing Depression in Parkinson disease. Washington, DC, 5-6 December 2003.
4. Parkinson disease blues (and reds and yellows): Neuroimaging of depression in PD. Invited lecture at British Association for Psychopharmacology. Oxford, England, 25 July 2006.
5. Diagnosing and treating Tourette syndrome. Wayne State University / Children's Hospital of Michigan Department of Neurology Grand Rounds (CDC / Tourette Syndrome Association medical education lecture). Detroit, MI, 7 December 2006.
6. Diagnosis and treatment of Tourette syndrome, 2007. University of Nevada Department of Psychiatry Grand Rounds (CDC / TSA medical education lecture). Reno, NV, 20 June 2007.
7. Is psychogenic dystonia a valid diagnosis? Invited lecture at 1st World Congress on Controversies in Neurology. Berlin, Germany, 8 September 2007. Abstract archived at <http://works.bepress.com/kjb/25/>
8. Diagnosis and treatment of Tourette syndrome, 2008. Neurology Grand Rounds, Louisiana State University Health Science Center (CDC / TSA medical education lecture). Shreveport, LA, 13 June 2008.
9. Diagnosis and treatment of Tourette syndrome 2009. University of Tennessee Health Sciences Center Distinguished Grand Rounds speaker (CDC / TSA medical education lecture). Memphis, TN, 13 February 2009.
10. Treatment of so-called psychogenic movement disorders. Invited lecture, Second International Congress on Psychogenic Movement Disorders. Washington, DC, 2-4 April 2009.
11. Diagnosis and treatment of Tourette syndrome. Department of Neurology and Psychiatry Grand Rounds, Saint Louis University School of Medicine, St. Louis, MO, 23 April 2009.
12. Diagnosis and treatment of Tourette syndrome 2009. CDC / TSA medical education lecture, Department of Clinical Neuroscience, University of North Dakota School of Medicine and

Health Sciences. Fargo, ND, 20 May 2009.

13. An evidence-based review of treatment efficacy in tic disorders: A report of the ANPA Committee on Research. Invited plenary lecture, 21st annual meeting, American Neuropsychiatric Association. Tampa, FL, 17-20 March 2010.
14. Tourette syndrome. CDC / TSA half-day medical education seminar, Wright State University Boonshoft School of Medicine / Wright-Patterson Medical Center. Dayton, OH, 30 June 2010.
15. Tourette syndrome. University of North Carolina at Chapel Hill Department of Psychiatry Grand Rounds (CDC / TSA medical education lecture). Chapel Hill, NC, 14 September 2011.
16. The TSA Neuroimaging Consortium. Invited lecture to Tourette Syndrome Association Scientific Advisory Board and Medical Advisory Board, Atlanta, GA, 17 January 2013.
17. Tourette syndrome throughout life: From “pre-Tourette’s” to geriatric tics. Invited plenary lecture, 24th annual meeting, American Neuropsychiatric Association. Boston, MA, 6 April 2013.
18. Diagnosis and treatment of Tourette syndrome. CDC / TSA medical education lecture, Clinical and Basic Neuroscience course, Philadelphia College of Osteopathic Medicine, Philadelphia, PA, 20 Feb 2015.
19. Treatment of neurobehavioral disturbances in Parkinson’s disease: Novel approaches and clinical trial design considerations. Invited plenary lecture, 29th Annual Symposium, Parkinson Study Group. Fort Myers, Florida, 12 Sep 2015.
20. Chewing, rocking, pacing, echoing: Differential diagnosis and importance of stereotyped movements. Plenary lecture (and chair of symposium on stereotypies), 27th annual meeting, American Neuropsychiatric Association. San Diego, CA, 17 April 2016. Slides archived at F1000Res 2016, 5:387 (DOI: [10.7490/f1000research.1111462.1](https://doi.org/10.7490/f1000research.1111462.1)).
21. 3D statistical analysis of DBS effects. Invited lecture, M-DBS 2017: Models for Deep Brain Stimulation, Paris, 24 May 2017.
22. The relationship between stimulation site and clinical outcome. Invited lecture, Toward Connectomic Deep Brain Stimulation. Radcliffe Institute for Advanced Study, Cambridge, MA, 20 Sep 2017.
23. Brain structure in pediatric Tourette syndrome. Invited lecture, Measuring and Modulating Brain Networks in Brain Health Disorders, University of Nottingham Institute of Mental Health, Nottingham, UK, 08 Nov 2017.
24. Tourette highlights from 2018. Invited plenary lecture, 12th Annual European Conference on Tourette Syndrome and Tic Disorders, Hannover, Germany, 17 May 2019.

## **RESEARCH SUPPORT (GOVERNMENTAL)**

Principal Investigator: Theodore J. Cicero, Ph.D. (KJB: Trainee)  
Title: Biomedical Research Training in Drug Abuse (Institutional Research Training Grant)  
Agency: NIH NIAAA, 5 T32 DA07261  
Award Period: 7/1994 - 6/1996

Principal Investigator: Kevin J. Black, M.D.  
Title: On-off mood change in Parkinson's disease  
Agency: NIH NINDS; K08 NS001898  
Award Period: 8/1996 - 7/2001  
Total Direct Cost(s): \$440,240

Principal Investigator: Kevin J. Black, M.D.  
Title: Testing dopaminergic function using pharmacologic fMRI  
Agency: NIH NINDS; 1 R21 NS042750 (priority score: 141, percentile: 6.1)  
Award Period: 12/1/2001 - 11/30/2004  
Total Direct Cost(s): \$237,500

Principal Investigator: Kevin J. Black, M.D.  
Title: Dopamine D1 effects on blood flow, metabolism, and BOLD  
Agency: NIH NINDS; 1 R01 NS044598-01 (priority score: 212)  
Award Period: 9/15/2002 - 8/31/2005 (extension to 2006)  
Total Direct Costs: \$712,500

Principal Investigator: William J. Powers, M.D. (Kevin J. Black, M.D.: Investigator)  
Title: Cerebral mitochondrial metabolism in neurodegeneration  
Agency: NIH NINDS; R01 NS041771  
Award Period: 4/1/2002 - 3/31/2005

Principal Investigator: Frank G. Gilliam, M.D. (Kevin J. Black, M.D.: Investigator)  
Title: Depression and health outcomes in refractory epilepsy  
Agency: NIH NINDS; R01 NS40808  
Award Period: 8/2001 - 7/2006 (KJB 1/2004 - 6/2006)

Principal Investigator: Tamara Hershey, Ph.D. (Kevin J. Black, M.D.: Investigator)  
Title: Neuro-cognitive impact of hypoglycemia in type 1 diabetes  
Agency: NIH NIDDK; R01 DK06483201  
Award Period: 7/2003 - 6/2008

Principal Investigator: Irene Richard, M.D. (Kevin J. Black, M.D.: Site P.I.)  
Title: Study of Antidepressants in Parkinson's Disease (SAD-PD)  
Agency: NINDS (subcontract from University of Rochester)  
Award Period: 2004-2008  
Total Direct Costs: TBA



Principal Investigator: Kevin J. Black, M.D.

Title: Dopaminergic Effects on Cortical Function in Tourette's

Agency: NIH NIMH; R01 MH073856 (priority score 137; percentile: 8.5)

Award Period: 2/2006 - 1/2011

Total Direct Costs: \$1,314,223

Principal Investigator: Kenneth Polonsky, M.D. (Kevin J. Black, M.D.: key personnel on "Brain, Behavior and Performance" core)

Title: Washington University Institute of Clinical and Translational Sciences

Agency: NIH NCRR; UL1 RR024992

Award Period: 10/2007-5/2012

Principal Investigator: Tamara Hershey, Ph.D. (Kevin J. Black, M.D.: co-investigator)

Title: Mapping mood in the subthalamic nucleus in PD

Agency: NIH NIMH; R01 NS058797

Award Period: 7/1/08-6/30/13

Total Direct Costs: \$1,552,725

Principal Investigator: Tamara Hershey, Ph.D. (Kevin J. Black, M.D.: key personnel)

Title: Glycemic control, brain structure and cognition in youth with T1DM

Agency: NIH NIDDK; 2 R01 DK064832-06

Award Period: 7/1/08-6/30/13

Total Direct Costs: \$1,250,000

Principal Investigator: Kevin J. Black, M.D.

Title: Quantitative dopamine receptor pharmacodynamics from fMRI

Agency: NIH NIMH; 1 R21 MH081080-01A1 priority score: 151 (an A2 resubmission was scored 130 but withdrawn when the A1 version was funded)

Award Period: 4/16/09-3/31/11

Total Direct Costs: \$275,000

Principal Investigator: Kevin J. Black, M.D. (applicant organization: Tourette Syndrome Association)

Title: 5th International Scientific Symposium on Tourette Syndrome

Agency: NIH (NINDS, NIMH, ORD); R13 NS066788-01 (priority score: 130)

Award Period: 6/2009

Total Direct Costs: \$43,000

Principal Investigator: Kevin J. Black, M.D.

Title: Quantitative dopamine receptor pharmacodynamics from fMRI (ARRA supplement)

Agency: NIH NIMH; 3 R21 MH081080-01A1S1

Award Period: 9/30/09-3/31/11

Total Direct Costs: \$119,018

Principal Investigator: Kevin J. Black, M.D.

Title: Training new investigators in neuroimaging and in the neuropsychiatry of movement disorders

Agency: NIH NIMH; 1 K24 MH087913-01 (priority score: 23)

Award Period: 12/1/2009-11/30/2014

Total Direct Costs: \$766,527

Principal Investigator: Tamara Hershey, Ph.D. (Kevin J. Black, M.D.: co-investigator)

Title: Central dopamine receptors in obesity

Agency: NIH NIDDK; 1R01DK085575-01

Award Period: 4/1/2010-1/31/2015

Total Direct Costs: ~\$1,400,000

Principal Investigator: Joel S. Perlmutter, M.D. (KJB: key personnel)

Title: Mechanisms of deep brain stimulation

Agency: NIH NINDS; 2 R01 NS041509-10

Award Period: 8/1/2011-7/31/2016

Principal Investigator: Kevin J. Black, M.D., and Tamara Hershey, Ph.D. (MPI)

Title: Testing the phasic dopamine release hypothesis in Tourette syndrome: pilot (“ToPDARTS pilot”)

Agency: NIH NIMH; 1R21MH098670-01 (priority score: 26)

Award Period: 8/1/2012-5/31/2014

Total Direct Costs: \$275,000

Principal Investigator: Tamara Hershey, Ph.D. (KJB: key personnel)

Title: Tracking neurodegeneration in early Wolfram syndrome.

Agency: NIH NICHD; R01 HD070855

Award Period: 8/17/2012-4/30/2017

Principal Investigator: Bradley L. Schlaggar, M.D., Ph.D., and Kevin J. Black, M.D. (MPI)

Title: Predicting outcome in children with new-onset tics using neuroimaging data

Agency: NIH NINDS; 1R21 NS091635

Award Period: 2/1/2015-1/31/2017

Total Direct Costs: \$275,000

Principal Investigator: Tamara Hershey, Ph.D. (KJB: key personnel)

Title: Early predictors of brain health and development in youth with T1DM

Agency: NIH NIDDK; 2 R01 DK064832-11

Award Period: 4/1/2016-3/31/2021

Principal Investigator: Kevin J. Black, M.D., and Bradley L. Schlaggar, M.D., Ph.D. (MPI)

Title: The New Tics study: A novel approach to pathophysiology and cause of tic disorders

Agency: NIH NIMH; 1R01 MH104030

Award Period: 6/9/2017-5/31/2022

Total Direct Costs: \$2,336,726

Principal Investigator: Kevin J. Black, M.D.

Title: Peripheral induction of inhibitory brain circuits to treat Tourette’s: pilot

Agency: The Washington University Institute of Clinical and Translational Sciences (supported by NIH CTSA grant UL1TR002345)

Award Period: 3/1/2021-2/28/2022

Total Direct Costs: \$50,000

## **RESEARCH SUPPORT (NON-GOVERNMENTAL)**

Principal Investigator: Kevin J. Black, M.D.  
Agency: McDonnell Center for Higher Brain Function  
Award Period: 7/94-6/95  
Total Direct Costs: \$10,000

Principal Investigator: Kevin J. Black, M.D.  
Title: PET studies of on-off mood change in Parkinson's disease  
Agency: NARSAD Young Investigator Award  
Award Period: 7/96-6/98  
Total Direct Costs: \$60,000

Principal Investigator: Kevin J. Black, M.D.  
Title: PET study of on-off mood changes  
Agency: American Parkinson Disease Association  
Award Period: 11/96-10/98  
Total Direct Costs: \$25,000

Principal Investigator: Kevin J. Black, M.D.  
Title: PET studies with NMB in Tourette Syndrome  
Agency: Tourette Syndrome Association  
Award Period: 4/98-4/99  
Total Direct Costs: \$39,865

Principal Investigator: Kevin J. Black, M.D.  
Title: Double-blind, placebo-controlled, fixed-dose, parallel group study of olanzapine for treatment of psychosis in patients with Parkinson's disease  
Agency: Lilly Research Laboratories  
Award Period: 02/1998 – 02/2004  
Total Direct Costs: \$79,250

Principal Investigator: Kevin J. Black, M.D.  
Title: Levodopa activation fMRI study of Tourette syndrome  
Agency: NARSAD Young Investigator Award  
Award Period: 7/99-12/01  
Total Direct Costs: \$60,000

Principal Investigator: Kevin J. Black, M.D.  
Title: A pilot study of levodopa for treatment of tics in children and adults  
Agency: Tourette Syndrome Association  
Award Period: 07/2000-06/2001 (extension to 8/2003)  
Total Direct Costs: \$25,214

Principal Investigator: Kevin J. Black, M.D.  
Title: Smoking history and personality supplement to neuroimaging studies in Parkinson's disease  
Agency: Dana Foundation  
Award Period: 05/01/2001-04/30/2004  
Total Direct Costs: \$100,000

Principal Investigator: Kevin J. Black, M.D.  
Title: Levodopa-stimulated dopamine release (pilot)  
Agency: Tourette Syndrome Association  
Award Period: 7/2003-6/2004  
Total Direct Costs: \$68,182

Principal Investigator: Kevin J. Black, M.D.  
Title: Levodopa challenge PET study of depression in Parkinson's disease  
Agency: Washington University Center for Aging  
Award Period: 5/2003-4/2004  
Total Direct Costs: \$29,997

Principal Investigator: Lei Wang, Ph.D. (Kevin J. Black, M.D.: Investigator)  
Title: Morphological abnormalities of the thalamus and basal ganglia in Tourette syndrome by computational anatomy  
Agency: Tourette Syndrome Association  
Award Period: 4/2004-3/2005  
Total Direct Costs: \$74,250

Principal Investigator: Kevin J. Black, M.D.  
Title: Levodopa-stimulated dopamine release II  
Agency: Tourette Syndrome Association  
Award Period: 5/2005-4/2006  
Total Direct Costs: \$74,000

Principal Investigator: Kevin J. Black, M.D.  
Title: Pilot Collaborative Studies for Pharmacological fMRI  
Agency: McDonnell Center for Higher Brain Function  
Award Period: 7/05-6/07  
Total Direct Costs: \$80,000

Site P.I.: Kevin J. Black, M.D.  
Title: Safety and efficacy of melperone in the treatment of patients with psychosis associated with Parkinson's disease (OV-1003)  
Agency: Ovation Pharmaceuticals  
Award Period: 2007  
Total Direct Costs: TBA

Friedman JH: Melperone is ineffective in treating Parkinson's disease psychosis. *Mov Disord* 2012; 27(6):803-804. [22362330](https://doi.org/10.1002/mds.24942) DOI: [10.1002/mds.24942](https://doi.org/10.1002/mds.24942) See also <https://clinicaltrials.gov/ct2/show/NCT00125138> .

Site P.I.: Kevin J. Black, M.D.

Title: Open-label follow up study of melperone in the treatment of patients with psychosis associated with Parkinson's disease (OV-1005)

Agency: Ovation Pharmaceuticals

Award Period: 2007

Total Direct Costs: TBA

Principal Investigator: Kevin J. Black, M.D. (single-site study)

Title: A randomized, double-blind, placebo-controlled, two-way cross-over study to explore the effects of 7 days dosing with SYN115 20 mg p.o. BID or 60 mg p.o. BID on clinical and fMRI response to intravenous levodopa in patients with mild to moderate Parkinson's disease

Agency: Synosia Therapeutics, Inc.

Award Period: 3/2008 - 5/2009

Total Direct Costs: \$338,242

Principal Investigator: Kevin J. Black, M.D.

Title: Finding tics in the community without putting a doctor on every corner

Agency: Tourette Syndrome Association

Award Period: 4/1/2008–3/31/2009

Total Direct Costs: \$61,825

Principal Investigator: Cathy W. Striley, Ph.D., MSW, MPE (KJB: Investigator)

Title: Uncovering disparities in TS prevalence and identification between Caucasians and African-Americans

Agency: Tourette Syndrome Association

Award Period: 4/2010–3/2011

Total Direct Costs: \$75,000

Co-Principal Investigators: Kevin J. Black, M.D., and Bradley L. Schlaggar, M.D., Ph.D.

Title: Tourette Syndrome Association neuroimaging consortium pilot

Agency: Tourette Syndrome Association

Award Period: 7/1/2010–6/30/2012

Total Direct Costs: \$500,000

Principal Investigator: Kevin J. Black, M.D.

Title: Pilot funding for pHMRI with ASL

Agency: McDonnell Center for Systems Neuroscience at Washington University

Award Period: 5/2011–7/2011

Total Direct Costs: \$16,833

Site PI: Kevin J. Black, M.D.

Title: A Multi-Center, Placebo-Controlled, Double-Blind Trial to Examine the Safety and Efficacy of Pimavanserin in the Treatment of Psychosis in Parkinson's Disease (ACP-103-020)

Agency: Acadia Pharmaceuticals

Award Period: 2011-2013

Total Direct Costs: \$42,491

Site PI: Kevin J. Black, M.D.

Title: A Multi-Center, Open-Label Extension Study to Examine the Safety and Tolerability of ACP-103 in the Treatment of Psychosis in Parkinson's Disease (ACP-103-015)

Agency: Acadia Pharmaceuticals

Award Period: 2011-2016

Total Direct Costs: TBA

Principal Investigator: Kevin J. Black, M.D.

Title: A new collaboration with Abby Hollander, M.D.

Agency: McDonnell Center for Systems Neuroscience at Washington University

Award Period: 10/2014–9/2015

Total Direct Costs: \$40,000

Site PI: Kevin J. Black, M.D.

Title: A Phase 1b, Open-Label, Multiple-Dose Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of NBI-98854 in Children and Adolescents With Tourette Syndrome (Study No. NBI-98854-1403)

Agency: Neurocrine Biosciences, Inc.

Award Period: 2014-2015

Total Direct Costs: ~\$0

Site PI: Kevin J. Black, M.D.

Title: Ecopipam Treatment of Tourette's Syndrome in Subjects 7-17 Years (Study # PSY302)

Agency: Psyadon Pharmaceuticals

Award Period: 2015-2016

Total Direct Costs: \$18,357

Principal Investigator: Deanna J. Greene, Ph.D. (KJB: Unpaid consultant)

Title: Network Architecture of the Brain in Tourette Syndrome and its Phenotypic Subgroups

Agency: Tourette Syndrome Association

Award Period: 5/2015–4/2017

Total Direct Costs: \$136,000

Principal Investigator: Catherine W. Striley, PhD, MSW, MPE. (KJB: Consultant)

Title: Prevalence of TD and Tics among a Community-recruited Sample of Adults from Haiti

Agency: Tourette Syndrome Association

Award Period: 7/2015–6/2017

Total Direct Costs: \$136,000

Principal Investigator: Cheryl A. Richards, Ph.D. (KJB: Investigator)

Title: Testing a Pathophysiological Model of Complex Tics

Agency: Tourette Syndrome Association

Award Period: 7/2015–6/2017

Total Direct Costs: \$136,364

Principal Investigator: Samuel Klein, M.D. (KJB: investigator on PET-MRI sub-project)  
Title: Complex Effects of Dietary Manipulation on Metabolic Function, Inflammation and Health  
Agency: Barnes-Jewish Hospital Foundation (from Pershing Square Foundation)  
Award Period: 12/2015- 2018

Site PI: Kevin J. Black, M.D.  
Title: Safety and Efficacy Study of NBI-98854 in Adults with Tourette Syndrome (NBI-98854-1505)  
Agency: Neurocrine Biosciences, Inc.  
Award Period: 5/1/2016–4/30/2017  
Total Direct Costs: \$92,755

Site PI: Kevin J. Black, M.D.  
Title: An Open-Label, Safety and Tolerability Study of NBI-98854 for the Treatment of Subjects with Tourette Syndrome (NBI-98854-1601)  
Agency: Neurocrine Biosciences, Inc.  
Award Period: 6/2016–5/2017  
Total Direct Costs: TBA

PI: Kevin J. Black, M.D.  
Title: Meeting costs for Tourette syndrome investigators  
Agency: McDonnell Center for Systems Neuroscience at Washington University  
Award Period: 1/2017–5/2017  
Total Direct Costs: \$10,000

Site PI: Kevin J. Black, M.D.  
Title: A Randomized, Parallel-group, Multicenter Study to Evaluate the Efficacy, Safety, and Tolerability of SEP-363856 in Subjects with Parkinson's Disease Psychosis (SEP361-203)  
Agency: Sunovion Pharmaceuticals Inc.  
Award Period: 1/2017–2018  
Total Direct Costs: TBA

PI: Kevin J. Black, M.D.  
Title: Dopamine buffering capacity measured by pHMRI as a novel biomarker of disease progression in PD  
Agency: The Michael J. Fox Foundation for Parkinson's Research (Grant ID: 13280)  
Award Period: 3/2/2017–6/30/2019  
Total Direct Costs: \$352,283

Site PI: Kevin J. Black, M.D.  
Title: A Phase 2b, Randomized, Double-Blind, Placebo-Controlled, Dose Optimization Study to Assess the Safety, Tolerability, and Efficacy of NBI-98854 for the Treatment of Pediatric Subjects with Tourette Syndrome (NBI-98854-TS2003)  
Agency: Neurocrine Biosciences, Inc.  
Award Period: 11/2017–2018  
Total Direct Costs: TBA

Site PI: Kevin J. Black, M.D.  
Title: Open-Label Safety and Tolerability Study of NBI-98854 for the Treatment of Pediatric Subjects

With Tourette Syndrome (NBI-98854-TS2004)

Agency: Neurocrine Biosciences, Inc.

Award Period: 6/2018–2018

Total Direct Costs: TBA

Site PI: Kevin J. Black, M.D.

Title: Safety and Efficacy of Adjunctive Pimavanserin in Adults with Parkinson's Disease and Depression (ACP-103-048)

Agency: ACADIA Pharmaceuticals

Award Period: 2018

Total Direct Costs: 0

PI: Kevin J. Black, M.D.

Title: Tic Talk 2019 (TAA-CDC education and awareness chapter grant)

Agency: Tourette Association of America (to Greater Missouri chapter, TAA)

Award Period: 2019

Total Direct Costs: \$9,000

PI: Kevin J. Black, M.D.

Title: Tic Talk 2019

Agency: McDonnell Center for Systems Neuroscience

Award Period: 2019

Total Direct Costs: \$5,000

Site PI: Kevin J. Black, M.D.

Title: A Multicenter, Placebo-Controlled, Double-Blind, Randomized, Parallel-Group, Phase 2b Study to Evaluate the Efficacy and Safety of Ecopipam Tablets in Children and Adolescent Subjects with Tourette's Syndrome (EBS-101-CL-001)

Agency: Emalex Biosciences

Award Period: 2019-

Total Direct Costs: TBA

PI: Kevin J. Black, M.D.

Title: Tic Talk 2020 (TAA-CDC education and awareness chapter grant)

Agency: Tourette Association of America (to Washington University in St. Louis TAA Center of Excellence)

Award Period: 12/2019-7/2020

Total Direct Costs: \$10,000

PI: Kevin J. Black, M.D.

Title: Peripheral induction of inhibitory brain circuits to treat Tourette's: pilot

Agency: Washington University Institute of Clinical and Translational Sciences, Clinical & Translational Research Funding Program

(One of 18 funded from 81 initial proposals.)

Award period: 3/2021-2/2022

Total Direct Costs: \$50,000



## **TRAINEE / MENTEE RECORD**

### **Undergraduate students**

1999, 2000, 2003, 2004, 2006:

Mentor for the Summer Scholars in Biology Program (“prefreshmen” laboratory science scholarship)

2005, 2006 and previously:

Mentor for Mallinckrodt Institute of Radiology summer scholars

5/2007 Senior thesis co-advisor (with Joel Perlmutter MD) for Vanessa Lewis (Washington University undergraduate, thesis title “The Diagnostic Validity of Psychogenic Dystonia”)

5/2009 Senior thesis advisor for Miranda Lindburg (Washington University undergraduate, thesis title “Background and quality control analyses for a pharmacologic functional connectivity MRI study of cortical function in Tourette syndrome, with an interesting result on movement in task-control fMRI studies”)

2009 Mentor for C/SURE summer students

2011, 2013, 2015, 2017, 2018:

Mentor for ASPIRE summer students

2013 Mentor for U-STAR summer student and BioMedRAP summer student

5/2018 Senior thesis advisor for Haley Botteron (Washington University undergraduate, thesis title “Creating a pathophysiological model to predict blink suppression discomfort from blink timing”)

5/2018 Senior thesis advisor for Molly Charney (Washington University undergraduate, thesis title “Pharmacodynamic phMRI with joint estimation of the arterial drug input curve”)

### **Medical students / Graduate students**

7/2004 Dissertation committee member for Jason A. Kaufman (Ph.D. candidate in Anthropology at Washington University, dissertation title “Pattern and scaling of regional cerebral glucose metabolism in mammals”)

4/2006 Thesis committee member for Melissa A. Munn (candidate for Master of Psychiatric Epidemiology at WUSM, thesis title “Amygdala Volume Analysis in Female Twins with Major Depression”)

9/2008 Dissertation committee member for Hannah Sypher Locke (Ph.D. candidate in Psychology at Washington University, dissertation title “Motivational and personality influences on cognitive control and task performance”)

2010-2012 Dissertation committee member for Erin Dowd (PhD candidate in Neuroscience at Washington University; MSTP program)

### **Trainee awards**

2004 Mollie Gordon MD, AOA student research fellowship award

2006 Mollie Gordon MD, ANPA (American Neuropsychiatric Association) Young Investigator award

2006 Natalia Abraham MD, World Parkinson Congress student travel award

2008 Meghan C. Campbell PhD, Tourette Syndrome Association fellowship

2008 Meghan C. Campbell PhD, ANPA Young Investigator award

2014 Deanna Greene PhD, K01 award

2014 Deanna Greene PhD, NARSAD Young Investigator award

2017 Shan Siddiqi MD, ANPA Clinical Neuroscience Trainee Award  
2018 Shan Siddiqi MD, ANPA Young Investigator Award

## **PATENTS**

U. S. patent # [8,463,552](#) (issue date 11 Jun 2013), “Novel methods for medicinal dosage determination and diagnosis,” inventors Kevin J. Black and Jonathan M. Koller.

U. S. patent application # [15/697,250](#), filed 08 May 2013, “Novel methods for medicinal dosage determination and diagnosis,” inventors Kevin J. Black and Jonathan M. Koller (continuation claims from patent above).

International patent application (PCT), [WO 2012/060844](#), [WO 2012/061787](#), filed 05 Nov 2010, published 10 May 2012, “A2a antagonists as cognition and motor function enhancers,” inventors Stephen I. Bandak, Kevin J. Black, and Meghan L. Campbell. Assigned to Biotie Therapies, Inc.

U. S. patent application # [13/882,132](#), filed 04 Nov 2011, published 28 Nov 2013, “A2a antagonists as cognition and motor function enhancers,” inventors Stephen I. Bandak, Kevin J. Black, and Meghan C. Campbell. Assigned to Biotie Therapies, Inc.

**BIBLIOGRAPHY** (ORCID [0000-0002-6921-9567](https://orcid.org/0000-0002-6921-9567))Online at NCBI: [www.bit.ly/myncbiKJB](http://www.bit.ly/myncbiKJB)h-index = 40 ([www.bit.ly/KJBscholar](http://www.bit.ly/KJBscholar))**Peer-Reviewed Manuscripts**

1. Husain MM, **Black KJ**, Doraiswamy PM, Shah SA, Rockwell WJK, Ellinwood EH Jr., Krishnan KRR: Subcortical brain anatomy in anorexia and bulimia. *Biol Psychiatry* 1992; 31:735-738. PubMed PMID [1599990](https://pubmed.ncbi.nlm.nih.gov/1599990/) DOI: [10.1016/0006-3223\(92\)90284-7](https://doi.org/10.1016/0006-3223(92)90284-7)
2. **Black KJ**, Compton WM, Wetzel M, Minchin S, Farber NB, Rastogi-Cruz D: Assaults by patients on psychiatric residents at three training sites. *Hosp Community Psychiatry* 1994; 45(7):706-710. PubMed PMID [7927296](https://pubmed.ncbi.nlm.nih.gov/7927296/) DOI: [10.1176/ps.45.7.706](https://doi.org/10.1176/ps.45.7.706)
3. **Black KJ**: Diagnosing depression after stroke. *South Med J* 1995; 88(7):699-708. PubMed PMID [7597471](https://pubmed.ncbi.nlm.nih.gov/7597471/) DOI: [10.1097/00007611-199507000-00001](https://doi.org/10.1097/00007611-199507000-00001)
4. Sheline YI, **Black KJ**, Bardgett ME, Csernansky JG: Platelet binding characteristics distinguish placebo responders from nonresponders in depression. *Neuropsychopharmacology* 1995; 12(4):315-322. PubMed PMID [7576008](https://pubmed.ncbi.nlm.nih.gov/7576008/) DOI: [10.1016/0893-133X\(94\)00097-J](https://doi.org/10.1016/0893-133X(94)00097-J)
5. Harvey SA, **Black KJ**: The dexamethasone suppression test for diagnosing depression in stroke patients. *Ann Clin Psychiatry* 1996; 8(1):35-39. PubMed PMID [8743648](https://pubmed.ncbi.nlm.nih.gov/8743648/) DOI: [10.3109/10401239609149090](https://doi.org/10.3109/10401239609149090)
  - a. Free ePDF for the first 50 people after Feb., 2020: <https://www.tandfonline.com/eprint/QQ8UTKTDDQHUCM6JAHSE/full?target=10.3109/10401239609149090>
6. **Black KJ**, Videen TO, Perlmutter JS: A metric for testing the accuracy of cross-modality image registration: validation and application. *J Comput Assist Tomogr* 1996; 20(5):855-861. PubMed PMID [8797932](https://pubmed.ncbi.nlm.nih.gov/8797932/) DOI: [10.1097/00004728-199609000-00038](https://doi.org/10.1097/00004728-199609000-00038)
7. Sheline YI, **Black KJ**, Lin DY, Christensen GE, Gado MH, Brunsten BS, Vannier MW: Stereological MRI volumetry of the frontal lobe. *Psychiatry Res Neuroimaging* 1996; 67(3):203-214. PubMed PMID [8912959](https://pubmed.ncbi.nlm.nih.gov/8912959/) DOI: [10.1016/S0925-4927\(99\)00003-7](https://doi.org/10.1016/S0925-4927(99)00003-7)
8. Perlmutter JS, Stambuk MK, Markham J, **Black KJ**, McGee-Minnich L, Jankovic J, Moerlein SM: Decreased [<sup>18</sup>F]spiperone binding in putamen in idiopathic focal dystonia. *J Neurosci* 1997; 17(2):843-850. PubMed PMID [8987805](https://pubmed.ncbi.nlm.nih.gov/8987805/) Full text: <http://www.jneurosci.org/content/17/2/843.short> [**>200 citations**]
9. **Black KJ**, Sheline YI: Personality disorder scores improve with effective pharmacotherapy of depression. *J Affect Disord* 1997; 43(1):11-18. PubMed PMID [9127826](https://pubmed.ncbi.nlm.nih.gov/9127826/) DOI: [10.1016/S0165-0327\(96\)00101-2](https://doi.org/10.1016/S0165-0327(96)00101-2) [**>100 citations**]
10. **Black KJ**, Gado MH, Perlmutter JS: PET measurement of dopamine D<sub>2</sub> receptor-mediated changes in striatopallidal function. *J Neurosci* 1997; 17(9):3168-3177. PubMed PMID [9096151](https://pubmed.ncbi.nlm.nih.gov/9096151/) Full text: <http://www.jneurosci.org/content/17/9/3168.abstract>
11. **Black KJ**, Perlmutter JS: Septuagenarian Sydenham's with secondary hypomania. *Neuropsychiatry Neuropsychol Behav Neurol* 1997; 10(2):147-150. PubMed PMID [9150517](https://pubmed.ncbi.nlm.nih.gov/9150517/) Full text: <http://journals.lww.com/cogbehavneurol/toc/1997/04000>
12. Perlmutter JS, Tempel LW, **Black KJ**, Parkinson D, Todd RD: MPTP induces dystonia and parkinsonism: Clues to the pathophysiology of dystonia. *Neurology* 1997; 49(5):1432-1438. PubMed PMID [9371934](https://pubmed.ncbi.nlm.nih.gov/9371934/) DOI: [10.1212/WNL.49.5.1432](https://doi.org/10.1212/WNL.49.5.1432) [**>150 citations**]

13. **Black KJ**, Gado MH, Videen TO, Perlmutter JS: Baboon basal ganglia stereotaxy using internal MRI landmarks: validation and application to PET imaging. *J Comput Assist Tomogr* 1997; 21(6):881-886. PubMed PMID [9386276](#) DOI: [10.1097/00004728-199711000-00006](#)
14. **Black KJ**, Perlmutter JS: Can [<sup>18</sup>F]fluorodopa positron emission tomography help determine disease status in familial Parkinson's disease? *Neurology Network Commentary* [continued as [Lancet Neurology Network](#)] 1997; 1(5):308-314. [peer-reviewed invited review]
15. **Black KJ**, Öngür D, Perlmutter JS: Putamen volume in idiopathic focal dystonia. *Neurology* 1998; 51(3):819-824. PubMed PMID [9748033](#) DOI: [10.1212/WNL.51.3.819](#) [**>100 citations**]
16. Hershey T, **Black KJ**, Stambuk MK, Carl JL, McGee-Minnich L, Perlmutter JS: Altered thalamic response to levodopa in Parkinson's patients with dopa-induced dyskinesias. *Proc Natl Acad Sci U S A* 1998; 95(20):12016-12021. PubMed PMID [9751782](#) PubMed Central PMCID [PMC21757](#) DOI: [10.1073/pnas.95.20.12016](#)
17. Feiwel RJ, **Black KJ**, Snyder AZ, McGee-Minnich LA, MacLeod AK, Perlmutter JS: Diminished regional cerebral blood flow response to vibration in patients with blepharospasm. *Neurology* 1999; 52(2):291-297. PubMed PMID [9932946](#) DOI: [10.1212/WNL.52.2.291](#) [**≥75 citations**]
18. **Black KJ**: On the efficiency of stereologic volumetry as commonly implemented for three-dimensional digital images. *Psychiatry Res Neuroimaging* 1999; 90(1):55-64. PubMed PMID [10320211](#) DOI: [10.1016/S0925-4927\(99\)00003-7](#)
  - a. Full text available at <http://works.bepress.com/kjb/29/>
19. **Black KJ**, Hershey T, Gado MH, Perlmutter JS: Dopamine D<sub>1</sub> agonist activates temporal lobe structures in primates. *J Neurophysiol* 2000; 84(1):549-557. PubMed PMID [10899226](#) Full text: <http://jn.physiology.org/content/84/1/549>
20. **Black KJ**, Mink JW: Response to levodopa challenge in Tourette syndrome. *Mov Disord* 2000; 15(6):1194-1198. PubMed PMID [11104204](#) DOI: [10.1002/1531-8257\(200011\)15:6<1194::AID-MDS1019>3.0.CO;2-H](#)
21. Hershey T, **Black KJ**, Carl JL, Perlmutter JS: Dopa-induced blood flow responses in non-human primates. *Exp Neurol* 2000; 166(2):342-349. PubMed PMID [11085899](#) DOI: [10.1006/exnr.2000.7522](#)
22. **Black KJ**, Snyder AZ, Koller JM, Gado MH, Perlmutter JS: Template images for nonhuman primate neuroimaging. 1. Baboon. *NeuroImage* 2001; 14(3):736-743. PubMed PMID [11506545](#) DOI: [10.1006/nimg.2001.0752](#)
23. **Black KJ**, Koller JM, Snyder AZ, Perlmutter JS: Template images for nonhuman primate neuroimaging. 2. Macaque. *NeuroImage* 2001; 14(3):744-748. PubMed PMID [11506546](#) DOI: [10.1006/nimg.2001.0871](#)
24. Racette BA, Hartlein JM, Hershey T, Mink JW, Perlmutter JS, **Black KJ**: Clinical features and comorbidity of mood fluctuations in Parkinson's disease. *J Neuropsychiatry Clin Neurosci* 2002; 14(4):438-442. PubMed PMID [12426412](#) DOI: [10.1176/appi.neuropsych.14.4.438](#)

25. **Black KJ**, Hershey T, Koller JM, Videen TO, Mintun MA, Price JL, Perlmutter JS: A possible substrate for dopamine-related changes in mood and behavior: Prefrontal and limbic effects of a D3-preferring dopamine agonist. *Proc Natl Acad Sci U S A* 2002; 99(26):17113-17118. PubMed PMID [12482941](#) PubMed Central PMCID [139278](#) DOI: [10.1073/pnas.012260599](#) [**>125 citations**]
26. Kaufman JA, Phillips-Conroy J, **Black KJ**, Perlmutter JS: Asymmetric regional cerebral blood flow in sedated baboons measured by positron emission tomography (PET). *Am J Phys Anthropol* 2003; 121(4):369-377. PubMed PMID [12884319](#) DOI: [10.1002/ajpa.10181](#)
27. Hershey T, **Black KJ**, Carl JL, McGee-Minnich L, Snyder AZ, Perlmutter JS: Long term treatment and disease severity change brain responses to levodopa in Parkinson's disease. *J Neurol Neurosurg Psychiatry* 2003; 74(7):844-851. PubMed PMID [12810765](#) PubMed Central PMCID [PMC1738560](#) DOI: [10.1136/jnnp.74.7.844](#)
28. **Black KJ**, Carl JL, Hartlein JM, Warren SL, Hershey T, Perlmutter JS: Rapid intravenous loading of levodopa for human research: Clinical results. *J Neurosci Methods* 2003; 127(1):19-29. PubMed PMID [12865145](#) DOI: [10.1016/S0165-0270\(03\)00096-7](#)
29. Hershey T, **Black KJ**, Hartlein J, Barch DM, Braver TS, Carl JL, Perlmutter JS: Cognitive-pharmacologic fMRI in Tourette syndrome: A pilot study. *Biol Psychiatry* 2004; 55(9):916-925. PubMed PMID [15110735](#) DOI: [10.1016/j.biopsych.2004.01.003](#)
30. Hershey T, **Black KJ**, Hartlein J, Braver TS, Barch DM, Carl JL, Perlmutter JS: Dopaminergic modulation of response inhibition: An fMRI study. *Brain Res Cogn Brain Res* 2004; 20(3):438-448. PubMed PMID [15268921](#) DOI: [10.1016/j.cogbrainres.2004.03.018](#)
31. Racette BA, Esper GJ, Antenor J, **Black KJ**, Burkey A, Moerlein SM, Videen TO, Kotagal V, Ojemann JG, Perlmutter JS: Pathophysiology of parkinsonism due to hydrocephalus. *J Neurol Neurosurg Psychiatry* 2004; 75(11):1617-1619. PubMed PMID [15489399](#) PubMed Central PMCID [1738818](#) DOI: [10.1136/jnnp.2003.028449](#)
32. **Black KJ**, Hershey T, Hartlein JM, Carl JL, Perlmutter JS: Levodopa challenge neuroimaging of levodopa-related mood fluctuations in Parkinson disease. *Neuropsychopharmacology* 2005; 30(3):590-601. PubMed PMID [15602502](#) DOI: [10.1038/sj.npp.1300632](#)
33. Marsh L, McDonald WM, Cummings JL, Ravina B, **NINDS/NIMH Work Group on Depression and Parkinson's Disease**: Provisional diagnostic criteria for depression in Parkinson's disease: Report of an NINDS/NIMH work group. *Mov Disord* 2006; 21(2):148-158. PubMed PMID [16211591](#) DOI: [10.1002/mds.20723](#) [**>300 citations**]
34. Coburn K, Lauterbach EC, Boutros NN, **Black KJ**, Arciniegas DB, Coffey CE: The value of quantitative electroencephalography in clinical psychiatry: A report by the Committee on Research of the American Neuropsychiatric Association. *J Neuropsychiatry Clin Neurosci* 2006; 18:460-500. PubMed PMID [17135374](#) DOI: [10.1176/jnp.2006.18.4.460](#) [**>200 citations**]
35. Gordon MR, Markham J, Hartlein JM, Koller JM, Loftin S, **Black KJ**: Intravenous levodopa administration in humans based on a two-compartment kinetic model. *J Neurosci Methods* 2007; 159(2):300-307. PubMed PMID [16934332](#) DOI: [10.1016/j.jneumeth.2006.07.010](#)

36. Wang L, Lee DY, Bailey E, Hartlein J, Gado M, Miller MI, **Black KJ**: Validity of large-deformation high dimensional brain mapping of the thalamus and basal ganglia in adults with Tourette syndrome. *Psychiatry Res Neuroimaging* 2007; 154(2):181-190. PubMed PMID [17289354](#) PubMed Central PMCID [2859464](#) DOI: [10.1016/j.psychres.2006.08.006](#) [**>50 citations**]
37. Perantie D, Wu J, Koller J, Lim A, Warren S, **Black KJ**, Sadler M, White N, Hershey T: Regional brain volume differences associated with hyperglycemia and severe hypoglycemia in youth with type 1 diabetes. *Diabetes Care* 2007; 30(9):2331-2337. PubMed PMID [17575089](#) DOI: [10.2337/dc07-0351](#) [**>200 citations**]
38. Royall DR, Lauterbach EC, Kaufer D, Malloy P, Coburn KL, **Black KJ**, and the Committee on Research of the American Neuropsychiatric Association: The cognitive correlates of functional status: A review from the Committee on Research of the American Neuropsychiatric Association. *J Neuropsychiatry Clin Neurosci* 2007; 19(3):249-265. PubMed PMID [17827410](#) DOI: [10.1176/jnp.2007.19.3.249](#) [**>350 citations**]
39. Foster ER, **Black KJ**, Antenor-Dorsey JAV, Perlmutter JS, Hershey T: Motor asymmetry and substantia nigra volume are related to spatial delayed response performance in Parkinson disease. *Brain Cogn* 2008; 67(1):1-10. PubMed PMID [18022303](#) PubMed Central PMCID: [PMC2993690](#) DOI: [10.1016/j.bandc.2007.10.002](#)
40. Powers WJ, Videen TO, Markham J, **Black KJ**, Golchin N, Perlmutter JS: Cerebral mitochondrial metabolism in early Parkinson disease. *J Cereb Blood Flow Metab* 2008; 28(10):1754-1760. PubMed PMID [18575458](#) PubMed Central PMCID: [PMC2597083](#) DOI: [10.1038/jcbfm.2008.63](#)
41. Hershey T, Perantie DC, Wu J, Weaver PM, **Black KJ**, White NH: Hippocampal volumes in youth with type 1 diabetes. *Diabetes* 2010; 59(1):236-241. PubMed PMID [19833895](#) PubMed Central PMCID: [PMC2797927](#) DOI: [10.2337/db09-1117](#) [**>75 citations**]
42. **Black KJ**, Koller JM, Campbell MC, Gusnard DA, Bandak SI: Quantification of indirect pathway inhibition by the adenosine A<sub>2a</sub> antagonist SYN115 in Parkinson disease. *J Neurosci* 2010; 30(48):16284-16292. PubMed PMID [21123574](#) PubMed Central PMCID: [PMC3008651](#) DOI: [10.1523/JNEUROSCI.2590-10.2010](#)
  - a. Selected as an "Editors' Choice" article in *Science Translational Medicine* 2:63ec199, 22 Dec 2010, DOI: [10.1126/scitranslmed.3002060](#)
43. Friedman JH, Agarwal P, Alcalay R, **Black KJ**, Chou KL, Cote L, Dayalu P, Frank S, Hartlein J, Hauser RA, Lang AE, Marsh L, Marshall F, Moskowitz C, Ravina B, Riley D, Sanchez-Ramos J, Simon DK, Simuni T, Sutton J, Tuite P, Weintraub D, Zesiewicz T: Clinical vignettes in Parkinson's disease: A collection of unusual medication-induced hallucinations, delusions, and compulsive behaviours. *Int J Neurosci* 2011; 121(8):472-476. PubMed PMID [21663381](#) DOI: [10.3109/00207454.2011.578779](#)
44. Limsoontarakul S, Campbell MC, **Black KJ**: An fMRI study of emotional valence and arousal in Parkinson disease. *Parkinsons Dis* 2011; 2011:742907. PubMed PMID [21969917](#) PubMed Central PMCID: [PMC3198062](#) DOI: [10.4061/2011/742907](#)
45. Perantie DC, Koller JM, Weaver PM, Lugar HM, **Black KJ**, White NH, Hershey T: Prospectively determined impact of type 1 diabetes on brain volume during development. *Diabetes* 2011; 60(11):3006-3014. PubMed PMID [21953611](#) PubMed Central PMCID: [PMC3198062](#) DOI: [10.2337/db11-0589](#) [**>100 citations**]

46. Campbell MC, **Black KJ**, Weaver PM, Lugar HM, Videen TO, Tabbal SD, Karimi M, Perlmutter JS, Hershey T: Mood response to deep brain stimulation of the subthalamic nucleus in Parkinson disease. *J Neuropsychiatry Clin Neurosci* 2012; 24(1):28-36. PubMed PMID [22450611](#) PubMed Central PMCID: [PMC3354989](#) DOI: [10.1176/appi.neuropsych.11030060](#)
47. Richard IH, McDermott MP, Kurlan RM, Lyness JM, Como PG, Pearson NJ, Factor SA, Juncos JL, Serrano Ramos C, Brodsky MA, Manning C, Marsh L, Shulman LM, Fernandez HH, **Black KJ**, Pannisset M, Christine CW, Jiang W, Singer C, Horn S, Pfeiffer RF, Rottenberg DA, Slevin J, Elmer LW, Press D, Hyson HC, McDonald W: A randomized, double-blind, placebo-controlled trial of antidepressants in Parkinson disease. *Neurology* 2012; 78:1229-1236. PubMed PMID [22496199](#) PubMed Central PMCID: [PMC3324323](#) DOI: [10.1212/WNL.0b013e3182516244](#) [**>250 citations**]
48. Eisenstein SA, Koller JM, Piccirillo M, Kim A, Antenor-Dorsey JA, Videen TO, Snyder AZ, Karimi M, Moerlein SM, **Black KJ**, Perlmutter JS, Hershey T: Characterization of extrastriatal D<sub>2</sub> receptor binding of [<sup>18</sup>F](N-methyl)benperidol using PET imaging. *Synapse* 2012; 66(9):770-780. PubMed PMID [22535514](#) PubMed Central PMCID: [PMC3389593](#) DOI: [10.1002/syn.21566](#)
49. Nichols MJ, Hartlein JM, Eicken MGA, Racette BA, **Black KJ**: A fixed-dose randomized controlled trial of olanzapine for psychosis in Parkinson disease [*version 1; referees: 2 approved*]. *F1000Research* 2013; 2:150. PubMed PMID [24627787](#) PubMed Central PMCID: [PMC3907164](#) DOI: [10.12688/f1000research.2-150.v1](#) [**>500 downloads**]
50. **Black KJ**, Koller JM, Miller BD: Rapid quantitative pharmacodynamic imaging by a novel method: Theory, simulation testing and proof of principle. *PeerJ* 2013; 1:e117. PubMed PMID [23940831](#) PubMed Central PMCID: [PMC3740141](#) DOI: [10.7717/peerj.117](#) [**>600 downloads; cited in [Biome 8/23/2013](#)**]
51. Panagopoulos VN, Greene DJ, Campbell MC, **Black KJ**: Towards objectively quantifying sensory hypersensitivity: A pilot study of the “Ariana effect.” *PeerJ* 2013; 1:e121. PubMed PMID [23940834](#) PubMed Central PMCID: [PMC3740136](#) DOI: [10.7717/peerj.121](#) [**>200 downloads**]
52. Miller B, Marks LA, Koller JM, Newman BJ, Bretthorst GL, **Black KJ**: Prolactin and fMRI response to SKF38393 in the baboon. *PeerJ* 2013; 1:e195. PubMed PMID [24255811](#) PubMed Central PMCID: [PMC3817584](#) DOI: [10.7717/peerj.195](#) [**>250 downloads**]
53. Williams AC, McNeely ME, Greene DJ, Church JA, Warren SL, Hartlein JM, Schlaggar BL, **Black KJ**, Wang L: A pilot study of basal ganglia and thalamus structure by high dimensional mapping in children with Tourette syndrome [*version 1; referees: 2 approved*]. *F1000Research* 2013; 2:207. PubMed PMID [24715957](#) PubMed Central PMCID: [PMC3976104](#) DOI: [10.12688/f1000research.2-207.v1](#) [**>350 downloads**]
54. Eisenstein SA, Antenor-Dorsey JA, Gredysa DM, Koller JM, Bihun EC, Ranck SA, Arbeláez AM, Klein S, Perlmutter JS, Moerlein SM, **Black KJ**, Hershey T: A comparison of D<sub>2</sub> receptor specific binding in obese and normal-weight individuals using PET with (N-[<sup>11</sup>C]methyl)benperidol. *Synapse* 2013; 67(11):748-756. PubMed PMID [23650017](#) PubMed Central PMCID: [PMC3778147](#) DOI: [10.1002/syn.21680](#)

55. **Black KJ**, Snyder AZ, Mink JW, Revilla FJ, Tolia V, Moerlein SM, Perlmutter JS: Spatial reorganization of putaminal dopamine D<sub>2</sub>-like receptors in cranial and hand dystonia. PLOS ONE 2014; 9(2):e88121. PubMed PMID [24520350](#) PubMed Central PMCID: [PMC3919754](#) DOI: [10.1371/journal.pone.0088121](#) [>1,750 article views]
56. Greene DJ, Laumann TO, Dubis JW, Ihnen SK, Neta M, Power JD, Pruett JR Jr., **Black KJ**, Schlaggar BL: Developmental changes in the organization of functional connections between the basal ganglia and cerebral cortex. J Neurosci 2014; 34(17):5842-5854. PubMed PMID [24760844](#) PubMed Central PMCID: [PMC3996213](#) DOI: [10.1523/JNEUROSCI.3069-13.2014](#)
57. Eisenstein SA, Koller JM, Black KD, Ushe M, Tabbal SD, Karimi M, Campbell MC, Lugar HM, Hershey T, Perlmutter JS, **Black KJ**: Functional anatomy of subthalamic nucleus stimulation in Parkinson disease. Ann Neurol 2014; 76(2):279-295. PubMed PMID [24953991](#) PubMed Central PMCID: [PMC4172323](#) DOI: [10.1002/ana.24204](#)
58. Eisenstein SA, De Wispelaere WB, Campbell MC, Lugar HM, Perlmutter JS, **Black KJ**, Hershey T: Acute changes in mood induced by subthalamic deep brain stimulation in Parkinson disease are modulated by psychiatric diagnosis. Brain Stimul 2014; 7(5):701-708. PubMed PMID [25017671](#) PubMed Central PMCID: [PMC4167923](#) DOI: [10.1016/j.brs.2014.06.002](#)
59. Schechter JR, Greene DJ, Koller JM, **Black KJ**: A revised method for measuring distraction by tactile stimulation [*version 1; referees: 2 approved*]. F1000Res 2014; 3:188. PubMed PMID [25285209](#) PubMed Central PMCID: [PMC4176419](#) DOI: [10.12688/f1000research.4944.1](#) [>250 downloads]
60. Stewart SB, Koller JM, Campbell MC, **Black KJ**: Arterial spin labeling versus BOLD in direct challenge and drug-task interaction pharmacological fMRI. PeerJ 2014; 2:e687. PubMed PMID [25538867](#) PubMed Central PMCID: [PMC4266850](#) DOI: [10.7717/peerj.687](#) [>500 downloads]
61. **Black KJ**, Piccirillo ML, Koller JM, Hsieh T, Wang L, Mintun M: Levodopa effects on [<sup>11</sup>C]raclopride binding in the resting human brain [*version 1; referees: 3 approved*]. F1000Res 2015; 4:23. PubMed PMID: [26180632](#). PubMed Central PMCID: [PMC4490799](#) DOI: [10.12688/f1000research.5672.1](#) [>350 downloads]
62. Greene DJ, Koller JM, Robichaux-Viehoever A, Bihun E, Schlaggar BL, **Black KJ**: Reward enhances tic suppression in children within months of tic disorder onset. Dev Cogn Neurosci 2015; 11:65-74. PubMed PMID [25220075](#) PubMed Central PMCID: [PMC4323948](#) DOI: [10.1016/j.dcn.2014.08.005](#) [>1,100 article views by July, 2015]
63. Stewart SB, Koller JM, Campbell MC, Perlmutter JS, **Black KJ**: Additive global cerebral blood flow normalization in arterial spin labeling perfusion imaging. PeerJ 2015; 3:e834. PubMed PMID [25802806](#) PubMed Central PMCID: [PMC4369335](#) DOI: [10.7717/peerj.834](#) [>250 downloads]
64. Eisenstein SA, Bischoff AN, Gredysa DM, Antenor-Dorsey JAV, Koller JM, Al-Lozi A, Pepino MY, Klein S, Perlmutter JS, Moerlein SM, **Black KJ**, Hershey T: Emotional eating phenotype is associated with central dopamine D<sub>2</sub> receptor binding independent of body mass index. Sci Rep 2015; 5:11283. PubMed PMID [26066863](#) PubMed Central PMCID: [PMC4464302](#) DOI: [10.1038/srep11283](#)
65. Eisenstein SA, Gredysa DM, Antenor-Dorsey JA, Green L, Arbeláez AM, Koller JM, **Black KJ**, Perlmutter JS, Moerlein SM, Hershey T: Insulin, central dopamine D<sub>2</sub> receptors, and monetary



- reward discounting in obesity. PLOS ONE 2015 10(7):e0133621. PubMed PMID: [26192187](#)  
PubMed Central PMCID: [PMC4507849](#) DOI: [10.1371/journal.pone.0133621](#) [>3,000 views]
66. Richards CA, **Black KJ**: Tourette syndrome research highlights 2014 [*version 2; referees: 1 approved, 2 approved with reservations*]. F1000Res 2015; 4:69. PubMed PMID: [26512319](#) PubMed Central PMCID: [PMC4602330](#) DOI: [10.12688/f1000research.6209.2](#) [>400 downloads]
  67. Siddiqi SH, Creech ML, **Black KJ**: Orthostatic stability with intravenous levodopa. PeerJ 2015; 3:e1198. PubMed PMID: [26336641](#) PubMed Central PMCID: [PMC4556150](#) DOI: [10.7717/peerj.1198](#) [>250 downloads]
  68. Siddiqi SH, **Black KJ**, Womer FY: Impact of a structured review session on medical student psychiatry subject examination performance [*version 2; referees: 2 approved*]. F1000Res 2015; 4:897. PubMed PMID: [26594347](#) PubMed Central PMCID: [PMC4648197](#) DOI: [10.12688/f1000research.7091.2](#) [>250 downloads]
  69. Greene DJ, Schlaggar BL, **Black KJ**: Neuroimaging in Tourette syndrome: Research highlights from 2014-2015. Curr Dev Disord Rep 2015; 2(4):300-308. PubMed PMID: [26543796](#) PubMed Central PMCID: [PMC4629775](#) DOI: [10.1007/s40474-015-0062-6](#)  
a. Author's accepted manuscript available at <https://works.bepress.com/kjb/47/>
  70. Miller B, Lim AN, Heidebreder AF, **Black KJ**: An automated motion detection and reward system for animal training. Curēus 2015; 7(12):e397. PMID: [26798573](#) PubMed Central PMCID: [PMC4699987](#) DOI: [10.7759/cureus.397](#) [>500 downloads]
  71. Siddiqi SH, Geiger CL, Abraham NK, Karimi M, Perlmutter JS, **Black KJ**: The human experience with intravenous levodopa. Front Pharmacol 2016; 6:307. PubMed PMID: [26779024](#) PubMed Central PMCID: [PMC4701937](#) DOI: [10.3389/fphar.2015.00307](#) [>5,000 views]
  72. Greene DJ, **Black KJ**, Schlaggar BL: Considerations for MRI study design and implementation in pediatric and clinical populations. Dev Cogn Neurosci 2016; 18:101-112. PubMed PMID: [26336641](#) PubMed Central PMCID: [PMC4834255](#) DOI: [10.1016/j.dcn.2015.12.005](#)
  73. Greene DJ, Church JA, Dosenbach NUF, Nielsen AN, Adeyemo B, Nardos B, Petersen SE, **Black KJ**, Schlaggar BL: Multivariate pattern classification of pediatric Tourette syndrome using functional connectivity MRI. Dev Sci 2016; 19(4):581-598. PubMed PMID: [26834084](#) PubMed Central PMCID: [PMC4945470](#) DOI: [10.1111/desc.12407](#)
  74. Koller JM, Vachon MJ, Bretthorst GL, **Black KJ**: Rapid quantitative pharmacodynamic imaging with Bayesian estimation. Front Neurosci 2016; 10:144. PubMed PMID: [27092045](#) PubMed Central PMCID: [PMC4825616](#) DOI: [10.3389/fnins.2016.00144](#) [>1,600 views]
  75. **Black KJ**, Black ER, Greene DJ, Schlaggar BL: Provisional Tic Disorder: What to tell parents when their child first starts ticcing [*version 1; referees: 3 approved*]. F1000Res 2016; 5:696. PubMed PMID: [27158458](#) PubMed Central PMCID: [PMC4850871](#) DOI: [10.12688/f1000research.8428.1](#) [>900 downloads] [[Altmetric score](#) 19]
  76. Richards CA, **Black KJ**: Tourette syndrome research highlights 2015 [*version 1; referees: 3 approved*]. F1000Res 2016; 5:1493. PMID: [27429744](#) PubMed Central PMCID: [PMC4943293](#) DOI: [10.12688/f1000research.8769.1](#) [>750 downloads]
  77. Vachon MJ, Striley CW, Gordon MR, Schroeder ML, Bihun EC, Koller JM, **Black KJ**: VISIT-TS: A multimedia tool for population studies on tic disorders [*version 2; referees: 3 approved*].

- F1000Res 2016; 5:1518. PMID: [27853509](#) PubMed Central PMCID: [PMC5089139](#)  
DOI: [10.12688/f1000research.7196.2](#) [>250 downloads]
78. Eisenstein SA, Bogdan R, Love-Gregory L, Corral-Frías NS, Koller JM, **Black KJ**, Moerlein SM, Perlmutter JS, Barch DM, Hershey T: Prediction of striatal D2 receptor binding by *DRD2/ANKK1* TaqIA allele status. *Synapse* 2016; 70(10):418-431. PubMed PMID: [27241797](#). PubMed Central PMCID: [PMC4980198](#) DOI: [10.1002/syn.21916](#)
  79. Pepino MY, Eisenstein SA, Bischoff AN, Klein S, Moerlein SM, Perlmutter JS, **Black KJ**, Hershey T: Sweet dopamine: Sucrose preferences relate differentially to striatal D<sub>2</sub> receptor binding and age in obesity. *Diabetes* 2016; 65(9):2618-2623. PubMed PMID: [27307220](#). PubMed Central PMCID: [PMC5001180](#) DOI: [10.2337/db16-0407](#) [[Altmetric score](#) 287 (99<sup>th</sup> percentile)]
  80. Eisenstein SA, Bogdan R, Chen L, Moerlein SM, **Black KJ**, Perlmutter JS, Hershey T, Barch DM: Preliminary evidence that negative symptom severity relates to multilocus genetic profile for dopamine signaling capacity and D2 receptor binding in healthy controls and in schizophrenia. *J Psychiatr Res* 2017; 86:9-17. PubMed PMID: [27886638](#). PubMed Central PMCID: [PMC5272837](#) DOI: [10.1016/j.jpsychires.2016.11.007](#)
  81. Cavanna AE, **Black KJ**, Hallett M, Voon V: Neurobiology of the premonitory urge in Tourette's syndrome: Pathophysiology and treatment implications. *J Neuropsychiatry Clin Neurosci* 2017; 29(2):95-104. PubMed PMID: [28121259](#). PubMed Central PMCID: [PMC5409107](#) DOI: [10.1176/appi.neuropsych.16070141](#)
  82. \*Greene DJ, \*Williams AC III, Koller JM, Schlaggar BL, **Black KJ**, The Tourette Association of America Neuroimaging Consortium: Brain structure in pediatric Tourette syndrome. *Mol Psychiatry* 2017; 22:972-980. PubMed PMID: [27777415](#). PubMed Central PMCID: [PMC5431276](#) DOI: [10.1038/mp.2016.194](#) [[Altmetric score](#) 72 (96<sup>th</sup> percentile)]  
\*Equal contributors  
Correction for PubMed record only, *Mol Psychiatry* 2020; 25:3112. DOI: [10.1038/s41380-019-0382-8](#)
  83. **Black KJ**: Tourette syndrome research highlights from 2016 [*version 2; referees: 4 approved*]. *F1000Research* 2017; 6:1430. PubMed PMID: [29057070](#). PubMed Central PMCID: [PMC5621096](#) DOI: [10.12688/f1000research.12330.2](#) [>300 downloads]
  84. Black JK, Koller JM, **Black KJ**: TicTimer software for measuring tic suppression [*version 2; referees: 2 approved*]. *F1000Res* 2017; 6:1560. PubMed PMID: [29375812](#). PubMed Central PMCID: [PMC5770993](#) DOI: [10.12688/f1000research.12327.2](#) [>150 downloads]
  85. **Black KJ**: Treatment of Parkinson's disease psychosis. *Med Int Rev* 2017; 27(109):266-271. PubMed PMID: [30140115](#). PubMed Central PMCID: [PMC6103448](#) Full text: <http://interrev.com/mir/index.php/mir/article/view/120>
  86. Conelea CA, Wellen B, Woods DW, Greene DJ, **Black KJ**, Specht M, Himle MB, Coffey BJ, Lee H-J, Capriotti M: Patterns and predictors of tic suppressibility in youth with tic disorders. *Front Psychiatry* 2018; 9:188. PubMed PMID: [29875706](#). PubMed Central PMCID: [PMC5974106](#) DOI: [10.3389/fpsyt.2018.00188](#) [>1,300 views]
  87. Gourisankar A, Eisenstein SA, Trapp NT, Koller JM, Campbell MC, Ushe M, Perlmutter JS, Hershey T, **Black KJ**: Mapping movement, mood, motivation, and mentation in the subthalamic

- nucleus. *R Soc Open Sci* 2018; 5(7):171177. PubMed PMID: [30109035](#). PubMed Central PMCID: [PMC6083651](#) DOI: [10.1098/rsos.171177](#) [>500 downloads]
88. Hartmann A, Worbe Y, **Black KJ**: Tourette syndrome research highlights from 2017 [*version 1; referees: 3 approved*]. *F1000Res* 2018; 7:1122. PubMed PMID: [30210792](#). PubMed Central PMCID: [PMC6107994](#) DOI: [10.12688/f1000research.15558.1](#) [>400 downloads]
  89. Black JK, **Black KJ**: Software for web-based tic suppression training [*version 2; referees: 3 approved*]. *F1000Res* 2018; 6:2150. PubMed PMID: [30228859](#). PubMed Central PMCID: [PMC6117856](#) DOI: [10.12688/f1000research.13460.2](#)
    - a. Version 1, published 19 Dec 2017 DOI: [10.12688/f1000research.13460.1](#)
  90. Gilbert DL, Murphy TK, Jankovic J, Budman CL, **Black KJ**, Kurlan R, Coffman KA, McCracken J, Juncos J, Grant J, Chipkin RE: Ecopipam, a D1 receptor antagonist, for treatment of Tourette syndrome in children: A randomized, placebo-controlled crossover study. *Mov Disord* 2018; 33(8):1272-1280. PubMed PMID: [30192018](#). DOI: [10.1002/mds.27457](#)
  91. **Black KJ**, Nasrallah H, Isaacson S, Stacy M, Pahwa R, Adler CH, Alva G, Cooney JW, Kremens D, Menza MA, Meyer JM, Patkar AA, Simuni T, Morrissette DA, Stahl S: Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: An expert consensus. *CNS Spectr* 2018; 23(6):402-413. PubMed PMID: [30588905](#). DOI: [10.1017/S1092852918001359](#)
    - a. Preprint available at <http://works.bepress.com/kjb/68/>
    - b. Corrigendum at PubMed PMID: [31182180](#). DOI: [10.1017/S1092852919000932](#)
  92. Younce J, Davis AA, **Black KJ**: A systematic review and case series of ziprasidone for psychosis in Parkinson disease. *J Parkinsons Dis* 2019; 9(1):63-71. PubMed PMID: [30475775](#). PubMed Central PMCID: [PMC6398550](#) DOI: [10.3233/JPD-181448](#)
  93. Kim S, Greene DJ, Bihun EC, Koller JM, Hampton JM, Acevedo H, Reiersen AM, Schlaggar BL, **Black KJ**: Provisional Tic Disorder is not so transient. *Sci Rep* 2019; 9(1):3951. PubMed PMID: [30850688](#). PubMed Central PMCID: [PMC6408476](#) DOI: [10.1038/s41598-019-40133-4](#) [Altmetric score 30]
  94. Kim S, Greene DJ, Robichaux-Viehoever A, Bihun EC, Koller JM, Acevedo H, Schlaggar BL, **Black KJ**: Tic suppression in children with recent-onset tics predicts 1-year tic outcome. *J Child Neurol* 2019; 34(12):757-764. PubMed PMID: [31241402](#). PubMed Central PMCID: [PMC6733613](#) DOI: [10.1177/0883073819855531](#) [Altmetric score 118 (99<sup>th</sup> percentile)]
  95. Rose O, Hartmann A, Worbe Y, Scharf JM, **Black KJ**: Tourette syndrome research highlights from 2018 [*version 1; peer review: 2 approved*]. *F1000Res* 2019; 8:988. PubMed PMID: [31508215](#). PubMed Central PMCID: [PMC6719747](#) DOI: [10.12688/f1000research.19542.1](#)
  96. Gilliam FG, **Black KJ**, Carter J, Freedland KE, Sheline YI, Tsai WY, Lustman PJ: A trial of sertraline or cognitive behavior therapy for depression in epilepsy. *Ann Neurol* 2019; 86(4):552-560. PubMed PMID: [31359460](#). PMCID: [PMC7012268](#). DOI: [10.1002/ana.25561](#)
  97. Botteron HE, Richards CA, Nishino T, Ueda K, Acevedo HK, Koller JM, **Black KJ**: The urge to blink in Tourette syndrome. *Cortex* 2019; 120:556-566. PubMed PMID: [31525588](#). PubMed Central PMCID: [PMC6825887](#) DOI: [10.1016/j.cortex.2019.07.010](#)
  98. Nielsen AN, Gratton C, Church JA, Dosenbach NUF, **Black KJ**, Petersen SE, Schlaggar BL, Greene DJ: Atypical functional connectivity in Tourette syndrome differs between children and

- adults. *Biol Psychiatry* 2020; 87(2):164-173. PubMed PMID: [31472979](#). PubMed Central PMCID: [PMC6925331](#) DOI: [10.1016/j.biopsych.2019.06.021](#) [[Altmetric score 26](#)]  
 a. Preprint available at <https://doi.org/10.1101/459560>
99. Eisenstein SA, **Black KJ**, Samara A, Koller JM, Dunn JP, Hershey T, Klein S, Smith GI: Striatal dopamine responses to feeding are altered in people with obesity. *Obesity (Silver Spring)* 2020; 28(4):765-771. PubMed PMID: [32086877](#). PubMed Central PMCID: [PMC7093218](#) DOI: [10.1002/oby.22753](#)
100. **Black KJ**, Acevedo HK, Koller JM: Dopamine buffering capacity imaging: A pharmacodynamic fMRI method for staging Parkinson disease. *Front Neurol* 2020; 11:370. PubMed PMID: [32477245](#). PubMed Central PMCID: [PMC7232584](#) DOI: [10.3389/fneur.2020.00370](#)
101. **Black KJ**, Kim S, Schlaggar BL, Greene DJ: The New Tics study: A novel approach to pathophysiology and cause of tic disorders. *J Psychiatr Brain Sci* 2020; 5(3):e200012. PubMed PMID: [32587895](#). PubMed Central PMCID: [PMC7316401](#) DOI: [10.20900/jpbs.20200012](#)
102. Kim S, Greene DJ, Badke D'Andrea C, Bihun EC, Koller JM, O'Reilly B, Schlaggar BL, **Black KJ**: Hippocampal volume in Provisional Tic Disorder predicts tic severity at 12-month follow-up. *J Clin Med* 2020; 9(6):1715. PubMed PMID: [32503289](#). PubMed Central PMCID: [PMC7355974](#) DOI: [10.3390/jcm9061715](#)
103. Black JK, Koller JM, **Black KJ**: TicTimer Web: Software for measuring tic suppression remotely [version 1; awaiting peer review]. *F1000Res* 2020; 9:1264. DOI: [10.12688/f1000research.26347.1](#)
104. Hartmann A, Worbe Y, **Black KJ**: Tourette syndrome research highlights from 2019 [version 2; peer review: 2 approved]. *F1000Res* 2020; 9:1314. DOI: [10.12688/f1000research.27374.1](#)
105. **Black KJ**, Barton SK, Perlmutter JS: Presymptomatic testing and confidentiality in the age of the electronic medical record. *J Neuropsychiatry Clin Neurosci* 2021; 33(1):80-83. PubMed PMID: [32669021](#). DOI: [10.1176/appi.neuropsych.20030068](#)
106. Ueda K, Kim S, Greene DJ, **Black KJ**: Correlates and clinical implications of tic suppressibility. *Curr Dev Disord Rep* [in press].  
 a. Preprint on OSF.io DOI: [10.31219/osf.io/5sg2d](#)
107. **Black KJ**, Kim S, Yang NY, Greene DJ: Course of tic disorders over the lifespan. *Curr Dev Disord Rep* [submitted].  
 a. Preprint on OSF.io DOI: [10.31219/osf.io/vehjr](#)
- 108.

### Case Reports

109. **Black KJ**, Kilzieh N: Severe imipramine-induced myoclonus in a patient with psychotic bipolar depression, catatonia and schizencephaly. *Ann Clin Psychiatry* 1994; 6(1):45-49. PubMed PMID [7951645](#) DOI: [10.3109/10401239409148839](#)
110. **Black KJ**, Sheline YI: Paroxetine as migraine prophylaxis. *J Clin Psychiatry* 1995; 56(7):330-331. PubMed PMID [7615489](#)
111. **Black KJ**, Racette BA, Perlmutter JS: Preventing contractures in NMS/dystonia. *Am J Psychiatry* 1998; 155(9):1298-1299. PubMed PMID [9734560](#) DOI: [10.1176/ajp.155.9.1298a](#)  
 a. Title correction: *Am J Psychiatry* 1998;155(12):1800. DOI: [10.1176/ajp.155.12.1800](#)

112. Nemanich ST, McNeely ME, Earhart GM, Norris SA, **Black KJ**: A case of apparent upper-body freezing in Parkinsonism while using a wheelchair. *Front Neurol* 2017; 8:205. PubMed PMID: [28555128](#). PubMed Central PMCID: [PMC5409107](#) DOI: [10.3389/fneur.2017.00205](#)
113. **Black KJ**: Case Report: DSM–5 misses an edge case in tic disorders nosology [*version 1; peer review: 2 approved*]. *F1000Res* 2020; 9:505. PubMed PMID: [32595960](#). PubMed Central PMCID: [PMC7309051](#) DOI: [10.12688/f1000research.23991.1](#)

### **Chapters, Editorials, Book Reviews**

1. **Black KJ**: **Child of Silence** by Abigail Padgett [book review]. *Hosp Comm Psychiatry* 1993; 44(8):796-797. DOI: [10.1176/ps.44.8.796](#) [journal was later renamed *Psychiatric Services*]
2. **Black KJ**, Guze SB: Psychiatry and the medical model. Ch. 1 (pp. 3-14) *in* Guze SB (ed.), **Washington University Adult Psychiatry**. St. Louis: Mosby, 1997.
3. **Black KJ**, Guze SB: Diagnosis. Ch. 2 (pp. 15-26) *in* Guze SB (ed.), **Washington University Adult Psychiatry**. St. Louis: Mosby, 1997.
4. Farber NB, **Black KJ**: Psychiatric disorders associated with general medical conditions. Pp. 407-426 *in* Guze SB (ed.), **Washington University Adult Psychiatry**. St. Louis: Mosby, 1997.
5. Csernansky JG, **Black KJ**, Faustman WO: The interface between standard psychiatric and neuropsychological diagnosis. Pp. 311-346 *in* Maruish ME and Moses JA Jr (eds.), **Clinical Neuropsychology: Theoretical Foundations for Practitioners**. Mahwah, NJ: Lawrence Erlbaum Associates, 1997.
6. **Black KJ**, Botteron KN: Neuroimaging in anorexia nervosa and bulimia nervosa. Pp. 267-295 *in* Krishnan KRR, Doraiswamy PM (eds.), **Brain Imaging in Clinical Psychiatry**. New York: Marcel Dekker, 1997.
7. Perlmutter JS, Stambuk M, Markham J, **Black KJ**, McGee-Minnich L, Jankovic J, Moerlein SM: Decreased [<sup>18</sup>F]spiperone binding in putamen in dystonia. Pp. 161-168 *in* **Dystonia 3 (Advances in Neurology vol. 78)**. Philadelphia: Lippincott-Raven, 1998. PubMed PMID [9750913](#)
8. **Black KJ**, Mink JW: Neuropsychiatry of movement disorders. *Curr Opin Psychiatry* 1999; 12(3):313-319. Full text: [https://journals.lww.com/co-psychiatry/Fulltext/1999/05000/Neuropsychiatry\\_of\\_movement\\_disorders.11.aspx](https://journals.lww.com/co-psychiatry/Fulltext/1999/05000/Neuropsychiatry_of_movement_disorders.11.aspx) Or [http://digitalcommons.wustl.edu/psych\\_facpubs/10](http://digitalcommons.wustl.edu/psych_facpubs/10)
9. **Black KJ**: Tourette syndrome and other tic disorders. *eMedicine Journal* 2(11), November 12, 2001 (<http://www.emedicine.com/neuro/topic664.htm>).
  - a. **Black KJ**, Webb H: updated 29 October 2004 and 22 March 2006.
  - b. **Black KJ**: updated 12 Aug 2008. [www.bit.ly/2URGQNG](http://www.bit.ly/2URGQNG)
10. **Black KJ**: Review of **Psychiatric Neuroimaging Research: Contemporary Strategies**, Dougherty and Rauch, eds. *J Clin Psychiatry* 2002; 63(11):1052.
11. **Black KJ**, Koller JM, Snyder AZ, Perlmutter JS: Atlas template images for nonhuman primate neuroimaging: baboon and macaque. Pp. 91-102 (ch. 6) *in* Conn PM (ed.), **Methods in Biological Imaging A (Methods in Enzymology, vol. 385)**. New York: Elsevier, 2004. *Also cited as* *Methods Enzymol* 2004; 385:91-102. PubMed PMID [15130735](#) DOI: [10.1016/S0076-6879\(04\)85006-7](#)

12. **Black KJ**: Psychiatry and the medical model. Pp. 3-14 (ch. 1) *in* Rubin EH, Zorumski CF: **Adult Psychiatry**. (Blackwell's Neurology and Psychiatry Access series [no volume number], series ed. David RB.) Bristol, U.K.: Blackwell, 2005.
13. **Black KJ**: Diagnosis. Pp. 15-23 (ch. 2) *in* Rubin EH, Zorumski CF: **Adult Psychiatry**. (Blackwell's Neurology and Psychiatry Access series [no volume number], series ed. David RB.) Bristol, U.K.: Blackwell, 2005.
14. Farber NB, **Black KJ**: Psychiatric disorders associated with general medical conditions. Pp. 384-401 (ch. 27) *in* Rubin EH, Zorumski CF: **Adult Psychiatry**. (Blackwell's Neurology and Psychiatry Access series [no volume number], series ed. David RB.) Bristol, U.K.: Blackwell, 2005.
15. **Black KJ**: Review of **Brain Stimulation in Psychiatric Treatment**, Lisanby SH, ed. *J Clin Psychiatry* 2005; 66(11):1496.
16. Taber KH, **Black KJ**, Hurley RA. Blood flow imaging of the brain: 50 years experience. *J Neuropsychiatry Clin Neurosci* 2005; 17(4): 441-446. PubMed PMID [16387981](#)  
DOI: [10.1176/jnp.17.4.441](#)
17. **Black KJ**, Pandya A. Depression in Parkinson disease. Pp. 199-237 *in* Gilliam F, Kanner AM, Sheline YI: **Depression and Brain Dysfunction**. New York: Taylor & Francis, 2006.  
<https://books.google.com/books?id=Y6oMTJZACVsC&pg=PA199>
18. **Black KJ**: Sex, lies and neuroimaging. Review of the book **Hardwired Behavior: What Neuroscience Reveals About Morality** by Tancredi LR. *PsycCRITIQUES—Contemporary Psychology: APA Review of Books* 51(17): article 18, 26 April 2006. DOI: [10.1037/a0002295](#)  
a. Available at: <http://cdm15960.contentdm.oclc.org/cdm/singleitem/collection/p15960coll21/id/48824/rec/1>
19. **Black KJ**, Friedman JH: Repetitive and impulsive behaviors in treated Parkinson disease [invited editorial]. *Neurology* 2006; 67(7):1118-1119. PubMed PMID [17030743](#)  
DOI: [10.1212/01.wnl.0000243252.71365.81](#)
20. **Black KJ**: Pain. Pp. 286-300 (ch. 12) *in* Coffey CE, McAllister T, Silver J: **Guide to Neuropsychiatric Therapeutics**. Baltimore: Lippincott Williams & Wilkins, 2006.  
[https://books.google.com/books?id=ZP9h\\_5vA-sgC&pg=PA286](https://books.google.com/books?id=ZP9h_5vA-sgC&pg=PA286)
21. **Black KJ**: 'Stop doing that!' Recognizing and managing tics. *Mo Med* 2008; 105(1):53-56. PubMed PMID [18300606](#)
22. Schlaggar BL, **Black KJ**, Powell SK: Diagnosis and treatment of Tourette syndrome and related disorders. *Pediatric UPDATE* volume 28, number 8, published February, 2008.  
([http://www.pedupdate.com/?gp\\_page=p\\_onecourse&gp\\_skey=214](http://www.pedupdate.com/?gp_page=p_onecourse&gp_skey=214))
23. Taber KH, **Black KJ**, Hurley RA: Blood flow imaging of the brain: 50 years' experience. Ch. 1 (pp. 3-10) *in* Hurley RA, Taber KH: **Windows to the Brain: Insights from Neuroimaging**. Arlington, VA: American Psychiatric Publishing, Inc., 2008.
24. **Black KJ**, Hershey T, Moerlein SM, Perlmutter JS: Neuroimaging in baboons. Pp. 327-350 [no chapter number] *in* VandeBerg JL, Williams-Blangero S, Tardif SD (eds.), **The Baboon in Biomedical Research**. New York: Springer, 2009. <http://www.springerlink.com/content/978-0-387-75990-6> DOI: [10.1007/978-0-387-75991-3\\_17](#)

25. **Black KJ**, Koller JM, Snyder AZ, Perlmutter JS: Atlas template images for nonhuman primate neuroimaging: baboon and macaque. Ch. 4 (pp. 55-66) *in* Conn PM (ed.): **Essential Bioimaging Methods**. Burlington, MA: Academic Press, 2009.  
<https://books.google.com/books?id=luXzcpIngicC&pg=PA54>
26. **Black KJ**: Deep brain stimulation for Tourette syndrome [invited editorial for journal's "patient page"]. **Neurology** 2009; 73:e87-e90. PubMed PMID [19858454](#)  
DOI: [10.1212/WNL.0b013e3181c284b3](#)
27. **Black KJ**: Tics. Chapter 385 (vol. 3, pp. 231-236) *in* Kompoliti K, Verhagen Metman L (eds.), **Encyclopedia of Movement Disorders**. Oxford: Elsevier (Academic Press), 2010.  
[http://www.elsevier.com/wps/product/cws\\_home/721402](http://www.elsevier.com/wps/product/cws_home/721402) DOI: [10.1016/B978-0-12-374105-9.00385-3](#)
28. **Black KJ**: **Disturbances of the Mind** by Douwe Draaisma [book review]. *J Neuropsychiatry Clin Neurosci* 2010; 22(4):452. DOI: [10.1176/jnp.2010.22.4.452](#)
29. **Black KJ**, Applewhite B: Pharmacotherapy. Chapter 40 (pp. 284-288) *in* Hallett M, Lang AE, Jankovic J, Fahn S, Halligan PW, Voon V, Cloninger CR (eds.), **Psychogenic Movement Disorders and Other Conversion Disorders**. New York: Cambridge University Press, 2011.  
<http://www.cambridge.org/aus/catalogue/catalogue.asp?isbn=9781107007345>
30. **Black KJ**: A new (old) treatment option for depression in Parkinson disease. [invited editorial] **Am J Psychiatry** 2011; 168(10):1015-1016. PubMed PMID [21969043](#)  
DOI: [10.1176/appi.ajp.2011.11071124](#)
31. Greene DJ, **Black KJ**, Schlaggar BL: Neurobiology and functional anatomy of tic disorders. Chapter 12 (pp. 238-275) *in* Martino D, Leckman JF (eds.), **Tourette Syndrome**. Oxford: Oxford University Press, 2013. DOI: 10.1093/med/9780199796267.003.0012  
a. Full text: <http://global.oup.com/academic/product/tourette-syndrome-9780199796267>
32. **Black KJ**, Jankovic J, Hershey T, McNaught KStP, Mink JW, Walkup J: Progress in research on Tourette syndrome. *J Obsessive Compuls Relat Disord* 2014; 3(4):359-362. PubMed PMID [25436182](#) PMCID: [PMC4243166](#) DOI: [10.1016/j.jocrd.2014.03.005](#) [>600 article views by July, 2015]  
a. Author's accepted manuscript available at <http://works.bepress.com/kjb/31/>
33. **Black KJ**: [F1000Research: Tics](#) welcomes you to 21st century biomedical publishing [*version 1; referees: not peer reviewed*]. *F1000Res* 2014; 3:272. PubMed PMID [25580234](#) PMCID: [PMC4288402](#)  
DOI: [10.12688/f1000research.5664.1](#) [>250 downloads]
34. Zelaya FO, Fernández-Seara MA, **Black KJ**, Williams SCR, Mehta MA: Perfusion in pharmacologic imaging. Chapter 72 (pp. 1083-1091) *in* Bammer R: **MR and CT Perfusion and Pharmacokinetic Imaging: Clinical Applications and Theory**. Part II: Clinical Applications. Philadelphia, PA: Lippincott Williams & Wilkins, 2016.  
<http://www.lww.com/Product/9781451147155>
35. Greene DJ, Kim S, **Black KJ**, Schlaggar BL: Neurobiology and functional anatomy of tic disorders. Chapter 12 *in* Martino D, Leckman JF (eds.), **Tourette Syndrome, 2nd ed.** Oxford: Oxford University Press, 2020 [in press].

36. Ueda K, **Black KJ**: The child with tics or other common movement disorders. *In* Kamat DM, Sivaswamy L (eds.), **Symptom-Based Approach to Pediatric Neurology**. New York: Springer, 2021 [in press].  
 a. Presubmission draft available, DOI: [10.31219/osf.io/chz7u](https://doi.org/10.31219/osf.io/chz7u)

### Non-refereed publications

1. **Black KJ**: Helicopters and Aunt Minnie [essay]. *N C Med J* 1992; 53(4):175-177. PubMed PMID [1594059](https://pubmed.ncbi.nlm.nih.gov/1594059/)
2. **Black KJ**: Medical informatics and psychiatric research [essay]. *Psychiatric Research Report* [American Psychiatric Association, Washington, DC] 1993; 8(3):20-21.
3. **Black KJ**: The mentor—why and who [essay]. *Psychiatric Research Report* 1994; 9(1):10.
4. **Black KJ**: Pathological laughing and crying [letter]. *Am J Psychiatry* 1994; 151(3):456.
5. **Black KJ**: The scientific method in clinical psychiatry (or, Research for the rest of us) [essay]. *Psychiatric Research Report* 1994; 9(2):10-11.
6. **Black KJ**: Organized schmoozing and other reasons to attend APA [essay]. *Psychiatric Research Report* 1994; 9(3):8-9.
7. Haller J, Botteron K, Brunnsden B, Sheline Y, Walkup R, **Black K**, Gado M, Vannier M: Hippocampal MR volumetry. *In* Robb RA (ed.), **Visualization in Biomedical Computing 1994**, SPIE Proceedings 1994; 2359:660-671. DOI: [10.1117/12.185228](https://doi.org/10.1117/12.185228)
8. **Black KJ**, Compton WM: Containing patient violence [letter]. *Psychiatr Serv* 1995; 46(4):409-410.
9. **Black KJ**: The ABCs of neuropsychiatry [letter]. *J Neuropsychiatry Clin Neurosci* 1995; 7(2):273. PubMed PMID [7626976](https://pubmed.ncbi.nlm.nih.gov/7626976/)
10. Sheline YI, **Black KJ**, Lin DY, Pimmel J, Wang P, Haller J, Csernansky J, Gado M, Walkup R, Brunnsden B, Vannier M: MRI volumetry of prefrontal cortex. *In* Loew MH (ed.), **Image Processing**, SPIE Proceedings 1995; 2434:766-770. DOI: [10.1117/12.208749](https://doi.org/10.1117/12.208749)
11. **Black KJ**: Anosognosia for depressive signs [letter]. *Am J Psychiatry* 1996; 153(2):298. [8561225](https://doi.org/10.1176/ajp.153.2.298)
12. **Black KJ**: Why I am a psychiatric scientist. *Journal of the California Alliance for the Mentally Ill* [Sacramento, CA] 1996; 7(4):39-40. Full text: <http://works.bepress.com/kjb/9>
13. **Black KJ** (1997, online 30 Oct 2013) A within-subject comparison of seizure duration with etomidate and methohexital in electroconvulsive therapy. *PeerJ PrePrints* 1:e87v1 DOI: [10.7287/peerj.preprints.87v1](https://doi.org/10.7287/peerj.preprints.87v1) [~300 downloads]
14. **Black KJ** (1997-2014, online 23 May 2014) Student safety and patient violence: The basic facts. <http://works.bepress.com/kjb/30>
15. **Black KJ** (1998-2019) Medical and ethical issues and Latter-day Saints. *SelectedWorks*.  
 a. Most recent update 25 Feb 2019, <http://works.bepress.com/kjb/26>
16. **Black KJ** (1999-2014) Behavior therapy for Tourette syndrome. [http://tourette.wikispaces.com/CBIT\\_for\\_tics](http://tourette.wikispaces.com/CBIT_for_tics)
17. **Black K**: Methods for volume measurement in 3D images [letter]. *Crit Rev Biomed Eng* 2001; 29(3):278. PubMed PMID [11730096](https://pubmed.ncbi.nlm.nih.gov/11730096/) Full text: <http://works.bepress.com/kjb/28/>



- a. See also PubMedCommons references [here](#) and [here](#).
18. **Black KJ**: Letter to the editor: Suicide and Mormon culture. SelectedWorks 11 May 2006. <http://works.bepress.com/kjb/27>
  19. **Black KJ**: Psychiatric screening for DBS [letter]. *Parkinsonism Relat Disord* 2007; 13(8):546. PubMed PMID [17303465](#) DOI: [10.1016/j.parkreldis.2006.12.007](#)
  20. Coburn KL, Lauterbach EC, Boutros NN, **Black KJ**, Arciniegas DB, Coffey CE: Drs. Coburn, Lauterbach, Boutros, Black, Arciniegas, and Coffey reply [letter]. *J Neuropsychiatry Clin Neurosci* 22(1):123-c.e4, 2010. DOI: [10.1176/jnp.2010.22.1.123.e4](#)
  21. Goldman JG, Pahwa R, Isaacson S, **Black K**: Parkinson's disease psychosis: A roundtable discussion. *Clinical Neurology News Supplement*, Jan. 2015, pp. 1-4 <http://bit.ly/1kHo0J> .  
(*Supplement supported by Acadia Pharmaceuticals.*)  
a. Available at <http://works.bepress.com/kjb/67/>
  22. **Black KJ**, Siddiqi SH: F1000Prime Recommendation of [Hirschtritt ME et al., *JAMA Psychiatry* 2015, 72(4):325-33]. F1000Prime, 07 Jan 2016; DOI: [10.3410/f.725359278.793512989](#).
  23. **Black KJ**, Siddiqi SH: F1000Prime Recommendation of [Leivonen S et al., *Child Psychiatry Hum Dev* 2016, 47(1):75-82]. F1000Prime, 10 Jan 2016; DOI: [10.3410/f.725401040.793514224](#).
  24. **Black KJ**: Suggestions for new NIH grant applicants. Authorea 08 Jul 2016. [https://www.authorea.com/users/4510/articles/118030/show\\_article](https://www.authorea.com/users/4510/articles/118030/show_article)  
a. Revised 05 Sep 2016, 04 Oct 2016  
b. Revised 21 Oct 2016. DOI: [10.22541/au.148787463.30762904](#)
  25. **Black KJ**: BillCorrectly: A software tool to help psychiatrists bill E&M codes appropriately. Authorea 05 Sep 2016. [https://www.authorea.com/users/4510/articles/126197/show\\_article](https://www.authorea.com/users/4510/articles/126197/show_article)  
a. Revised 04 Oct 2016. DOI: [10.22541/au.148787407.71705278](#)
  26. **Black KJ**, Okun MS: Simulated Patient Cases in Parkinson's Disease: Can You Diagnose and Treat These Patients? Medscape CME activity. 27 Dec 2016. [medscape.org/viewarticle/868446](https://www.medscape.org/viewarticle/868446)
  27. **Black KJ**: Smoke gets in your tics. Authorea 25 Apr 2017. DOI: [10.22541/au.149308896.61629534](#)  
a. Revised 18 Jan 2018.
  28. **Black KJ**: "But my department chair wants big-name journals": Gentle steps to open publishing. Authorea 04 Aug 2017. DOI: [10.22541/au.150188653.35495142](#)
  29. **Black KJ**: Taking a deeper look at Tourette syndrome. F1000 **blog**network, 27 September 2017. [www.bit.ly/F1000blog2017](http://www.bit.ly/F1000blog2017)
  30. **Black KJ**: F1000Prime Recommendation of [Schaefer SM et al., *Tremor Other Hyperkinet Mov (N Y)* 2017, 7:450]. F1000Prime, 21 Dec 2017; DOI: [10.3410/f.731288545.793540796](#).
  31. **Black KJ**: F1000Prime Recommendation of [Groth C et al., *J Am Acad Child Adolesc Psychiatr* 56(4):304-12]. F1000Prime, 21 Dec 2017; DOI: [10.3410/f.727465226.793540797](#).
  32. **Black KJ**: A measured response to CNN's article on Nuplazid®. [blog post] 19 Apr 2018. <https://sites.wustl.edu/blacklab/a-measured-response-to-cnns-article-on-nuplazid/>

33. **Black KJ**: F1000Prime Recommendation of [Baake V et al., J Neuropsychiatry Clin Neurosci early online DOI [10.1176/appi.neuropsych.18020031](https://doi.org/10.1176/appi.neuropsych.18020031)]. F1000Prime, 05 Jun 2018; DOI: [10.3410/f.733314893.793546488](https://doi.org/10.3410/f.733314893.793546488).
34. **Black KJ**: F1000Prime Recommendation of [Pérez-Vigil A et al., JAMA Neurol 2018 Published online DOI [10.1001/jamaneurol.2018.1194](https://doi.org/10.1001/jamaneurol.2018.1194)]. In F1000Prime, 12 Jun 2018; DOI: [10.3410/f.733319681.793546716](https://doi.org/10.3410/f.733319681.793546716).
35. **Black KJ**: Management of tardive dyskinesia. [blog post] 22 June 2018. <https://sites.wustl.edu/blacklab/management-of-tardive-dyskinesia-2018/>  
a. Revised 26 Mar 2019.
36. **Black KJ**: F1000Prime Recommendation of [Shimony JS et al., PLoS ONE 2018 13(9):e0202201]. In F1000Prime, 18 Sep 2018; DOI: [10.3410/f.733951349.793550543](https://doi.org/10.3410/f.733951349.793550543).
37. **Black KJ**: F1000Prime Recommendation of [Lee JY et al., J Neurol Neurosurg Psychiatr 2019 90(1):30-37]. In F1000Prime, 25 Jan 2019; DOI: [10.3410/f.734297467.793555237](https://doi.org/10.3410/f.734297467.793555237)
38. **Black KJ**: F1000Prime Recommendation of [Yu D et al., Am J Psychiatry 2019 176(3):217-227]. In F1000Prime, 12 Mar 2019; DOI: [10.3410/f.735183335.793557331](https://doi.org/10.3410/f.735183335.793557331)
39. **Black KJ**: F1000Prime Recommendation of [Lowe TL et al., Mov Disord Clin Pract 2019 6(1):40-45]. In F1000Prime, 30 May 2019; DOI: [10.3410/f.735078392.793556517](https://doi.org/10.3410/f.735078392.793556517)
40. **Black KJ**: F1000Prime Recommendation of [Leyland LA et al., Neurol Clin Pract 2020 10(1):29-39]. In F1000Prime, 27 Feb 2020; DOI: [10.3410/f.737408062.793571485](https://doi.org/10.3410/f.737408062.793571485)
41. Nielsen AN, Kim S, Gratton C, Church JA, **Black KJ**, Petersen SE, Schlaggar BL, Greene DJ: Age-dependent differences in functional brain networks are atypical in Tourette syndrome. medRxiv, 6 Apr 2020. DOI: [10.1101/2020.04.06.20049817](https://doi.org/10.1101/2020.04.06.20049817)

### Data and software

1. **Black KJ**, Videen TO, Perlmutter JS (1997) The “DH68” stereotactic atlas of baboon brain: definitions and reference data. Zenodo. DOI: [10.5281/zenodo.2579267](https://doi.org/10.5281/zenodo.2579267)
2. **Black KJ**, Hershey T, Gado MH, Perlmutter JS (1997) D&H atlas volumes of interest for baboon PET studies. Zenodo. DOI: [10.5281/zenodo.2579275](https://doi.org/10.5281/zenodo.2579275)
3. **Black KJ** (1999) Test program (“stereo”) for stereology. <http://www.nil.wustl.edu/labs/kevin/stereo.htm>
4. **Black KJ**, Snyder AZ, Koller JM, Gado MH, Perlmutter JS (2000) B2K template images for neuroimaging in baboon. Zenodo. DOI [10.5281/zenodo.1228293](https://doi.org/10.5281/zenodo.1228293) (also referenced as [www.purl.org/net/kbmd/b2k](http://www.purl.org/net/kbmd/b2k))
5. **Black KJ**, Koller JM, Snyder AZ, Perlmutter JS (2000) N2K template images for neuroimaging in *Macaca nemestrina*. <http://www.nil.wustl.edu/labs/kevin/ni/n2k/> (also referenced as [www.purl.org/net/kbmd/n2k](http://www.purl.org/net/kbmd/n2k))
6. **Black KJ**, Koller JM, Snyder AZ, Perlmutter JS (2005) Template images for neuroimaging in *Macaca fascicularis*. <http://www.nil.wustl.edu/labs/kevin/ni/cyno/cyno.html> (also referenced as [www.purl.org/net/kbmd/cyno](http://www.purl.org/net/kbmd/cyno))

7. Vachon MJ, Striley CW, Gordon MR, Schroeder ML, Bihun EC, Koller JM, **Black KJ** (2016) VISIT-TS video (release 20160516). Zenodo. DOI: [10.5281/zenodo.55604](https://doi.org/10.5281/zenodo.55604)
8. Black JK, **Black KJ** (2018) TicTrainer v.3 (Version 3.0). Zenodo. DOI: [10.5281/zenodo.1325945](https://doi.org/10.5281/zenodo.1325945)

### Selected posters and slides

1. **Black KJ**, Snyder AZ, Tolia VN, Perlmutter JS (1999) A group-averaged structural MRI study of primary focal dystonia. F1000Posters 2013, 4:392 (poster). <https://f1000research.com/posters/1093378>
2. **Black KJ** (2002) How to think about mental illness. <https://f1000research.com/slides/8-225>
3. **Black KJ**, Hershey T, Koller JM, Carl JL, Perlmutter JS (2002) Mapping and quantification of dopamine D2 receptor activation. F1000Posters 2013, 4:251 (slides). <https://f1000research.com/slides/1093169>
4. Black CF, Hartlein JM, Hershey T, Perlmutter JS, **Black KJ** (2003) A voxel-based morphometry study of Tourette syndrome. F1000Posters 2013, 4:91 (poster). <https://f1000research.com/posters/1092954>
5. Warren SL, Hartlein JM, **Black KJ** (2004) Clinical effects of an intravenous apomorphine protocol in Parkinson disease. F1000Posters 2013, 4:1223 (poster). <https://f1000research.com/posters/1094482>
6. Gordon M, Cologne SE, Hartlein JM, Koller JM, Schlaggar BL, Mink JW, **Black KJ** (2008) A pilot study of levodopa for treatment of tics in children and adults. F1000Posters 2013, 4:668 (poster). <https://f1000research.com/posters/1093664>
7. Black KD, Schafer W, Kessler P, **Black KJ** (2009) Efficacy of adjunctive music therapy for schizophrenia. F1000Posters 2013, 4:116 (slides). <https://f1000research.com/slides/1093002>
8. Black KD, **Black KJ**, Hershey T (2010) A preliminary test of the mnemonic hypometria hypothesis in Parkinson disease. F1000Posters 2013, 4:101 (poster). <https://f1000research.com/posters/1092989>
9. King AM, Hershey T, **Black KJ**, Koller JM, Perlmutter JS (2012) Pharmacological activation neuroimaging with levodopa and specific dopamine agonists in primate brain. F1000Posters 2013, 4:252 (poster). <https://f1000research.com/posters/1093157>
10. **Black KJ**: Chewing, rocking, pacing, echoing: Differential diagnosis and importance of stereotyped movements (slide presentation). F1000Res 17 Apr 2016, 5:387 (slides). DOI: [10.7490/f1000research.1111462.1](https://doi.org/10.7490/f1000research.1111462.1) [>1,700 views]